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Abstract 
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) is a lysosomal storage disease caused 
by autosomal recessive mutations in CLN3. Neuronal loss is thought to occur via 
glutamate excitotoxicity; however, little is known about neuron-astrocyte glutamate 
regulation in JNCL. We discovered that Cln3Δex7/8 astrocytes have significantly lower 
basal spontaneous Ca2+ oscillations and decreased responses to glutamate, indicating a 
disrupted signaling network.  Cln3Δex7/8 astrocytes also displayed significantly lower basal 
mitochondrial respiration and ATP production, suggesting impaired metabolic functions. 
Concurrent with diminished astrocyte metabolism and Ca2+ signaling, Cln3Δex7/8 neurons 
were hyper-responsive to glutamate stimulation. These studies suggest that CLN3 loss 
disrupts neuronal synaptic activity causing increased glutamate release, which 
astrocytes are unequipped to regulate due to reductions in Ca2+ signaling and energy 
metabolism. Therefore, a therapeutic capable of targeting several molecular deficits 
associated with JNCL would be an ideal. Cyclic AMP (cAMP) is a second messenger 
with pleiotropic effects, including regulating neuroinflammation, glutamate transporter 
expression, and neuron survival. We investigated whether three distinct 
phosphodiesterase-4 (PDE4) inhibitors could mitigate disease pathology in the Cln3Δex7/8 
mouse model. cAMP levels were significantly reduced in the Cln3Δex7/8 brain, which were 
restored by PF-06266047. PDE4 inhibitors significantly improved motor function, 
attenuated glial activation and lysosomal pathology, and restored glutamate transporter 
expression with no evidence of toxicity. These studies revealed neuroprotective effects 
of PDE4 inhibitors in Cln3Δex7/8 mice and support their therapeutic potential. However, 
PDE4 inhibitors do not provide a long-term treatment for JNCL because the CLN3 
mutation is still present.  Therefore, we explored a gene delivery approach for JNCL 
utilizing two self-complementary AAV9 (scAAV9) constructs with the MeCP2 and β-actin 
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promoters to drive low versus high transgene expression and to test efficacy in the 
Cln3Δex7/8 model.  Only the scAAV9/MeCP2-hCLN3 construct corrected motor deficits 
and attenuated glia activation and lysosomal pathology, possibly resulting from 
preferential viral promoter usage by neurons. This is the first demonstration of a 
systemic delivery route to restore CLN3 in vivo using scAAV9 and highlights the 
importance of promoter selection for disease modification. Collectively, these projects 
provide novel insights into CLN3 pathology and identify two promising modes of 
therapeutic advancement for this fatal lysosomal storage disease. 
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Chapter 1: Introduction 
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Lysosomal Storage Diseases 
Since the discovery of the lysosome nearly 60 years ago by Christian de Duve 
[1], the field of lysosomal storage diseases (LSDs) has expanded significantly. LSDs 
currently encompass approximately 70 genetically distinct diseases, with a collective 
incidence of 1:5000 live births annually [2]. LSDs account for roughly 14% of all inherited 
metabolic diseases [3, 4], among which the majority are autosomal recessive with the 
exception of mucopolysaccharidosis type II (MPS II) being inherited as an X-linked 
recessive trait [3]. A common denominator across all LSDs is lysosomal dysfunction 
originating from the loss of function or expression of lysosomal enzymes or other 
proteins that are vital for lysosomal homeostasis [5]. While the function of mutated 
molecules in some LSDs is well-characterized, in others, such as Niemann-Pick type C 
(NPC) and Juvenile Neuronal Ceroid Lipofuscinosis (JNCL; CLN3 disease), the normal 
function of mutated proteins is unknown [2, 6, 7]. Nevertheless, studies using mouse 
models and cells from affected patients, as well as lower species when available (i.e. 
yeast, Drosophila), have provided valuable information concerning the downstream 
sequelae of LSDs where the putative function of mutated molecules remains to be 
identified [8-13]. 
Lysosomes are membrane-bound organelles found in all eukaryotic cells, whose 
primary function is to degrade and recycle lipids, proteins, macromolecules, and 
intracellular organelles required for cellular homeostasis [14]. There are three main 
degradation pathways that converge in the lysosome[15]. Endocytosis and phagocytosis 
result in the internalization of extracellular components into endocytic vesicles, which 
then fuse to create endosomes[16]. Endosomes combine with Golgi transport vesicles 
carrying hydrolases to form late endosomes, which eventually mature into lysosomes as 
they continue to develop and acquire degradative enzymes. Autophagy degrades 
intracellular components, such as damaged, diseased, or senescent organelles by 
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transporting material to mature lysosomes via macroautophagy pathways. Lysosomes 
harbor over 60 different enzymes which include proteases, lipases, nucleases, 
glycosidase, and phospholipases that are responsible for lipid and protein degradation 
and recycling [5].  Lysosomal enzymes function at a pH < 5 that is maintained by 
vacuolar ATPases, which transport protons from the cytoplasm into the lumen [17, 18]. 
Other essential lysosomal components are integral membrane proteins, such as LAMP-1 
and LAMP-2, which regulate lysosomal movement, exocytosis, and maintain lysosomal 
membrane integrity [18-20]. Recently it was discovered that the lysosome plays a role in 
multiple cellular pathways other than degradation [18, 21]. For example, lysosomes have 
a central role in responding and controlling cellular reactions to nutrients. During cellular 
starvation, lysosomes cluster with autophagosomes in the perinuclear space for rapid 
degradation and recycling of proteins and amino acids to produce new molecules to 
maintain cellular functions [21]. Due to their substantial enzyme burden and low pH, it is 
vital that lysosomal membrane integrity is maintained because release of lysosomal 
contents would induce cell death [1, 22]. The lysosome is also capable of inducing 
programmed cell death via lysosomal membrane permeability (LMP) [23, 24]. LMP 
releases proteases, such as cathepsins, into the cytoplasm, which can activate multiple 
apoptotic pathways as well as the inflammasome [25, 26]. Disruptions in lysosomal 
function, such as loss of degradative enzymes or membrane proteins, can lead to the 
accumulation of undigested macromolecules, which is a hallmark feature of LSDs [27].       
 
 Lysosomal inclusions are a hallmark of LSDs, where the composition of 
inclusions can vary widely depending on the type of mutation to include a heterogeneous 
combination of sphingolipids, phospholipids, or galactosylceramide as well as proteins 
[28]. In general, most LSDs are typified by inclusions in both the central nervous system 
(CNS) and periphery, since affected proteins are generally universally expressed in the 
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lysosomes of all cells. Nevertheless, it is evident that the CNS is extremely vulnerable to 
impaired lysosomal function and, as such, numerous LSDs are associated with 
neurological sequalae. LSDs are often characterized into four subgroups based on the 
composition of lipid accumulation, namely, mucopolysaccharidoses, glycolipidoses, 
mucolipidoses, and glycoproteinoses [5, 29].  These glycolipids and glycoproteins 
comprise the main structural components of cell membranes and influence cellular 
trafficking, second messenger signaling, and cell-cell communication [30, 31]. Therefore, 
perturbations in membrane lipid recycling or breakdown consequently lead to disruptions 
in myelin production, molecular transport systems, apoptosis, and immune system 
activation [5]. While inclusions are a prominent biomarker and reflect lysosomal function, 
there has been no compelling evidence to suggest that inclusions directly cause 
neuronal death in JNCL. Inclusions form in multiple types of neurons in different brain 
regions; however, neurodegeneration is primarily seen in thalamocortical regions at later 
stages of the disease process (i.e 9-12 months in Cln3Δex7/8 mice [32, 33].  
 
Neuroinflammation in Lysosomal Storage Diseases: A common thread 
Neuroinflammation is typically elicited as a protective response following CNS 
injury, infection, or disease; however, heightened or chronic inflammation can exert 
detrimental effects on neural cells [34-36]. Inflammatory events are initiated in the CNS 
upon sensing danger-associated molecular patterns (DAMPs) or pathogen-associated 
molecular patterns (PAMPs) by resident microglia and astrocytes, often leading to the 
mobilization of peripheral leukocytes into the CNS [37]. The goal is a swift response to 
contain the insult, which is rapidly downregulated to avoid unnecessary bystander 
damage  [35]. This process is facilitated by several factors, including inflammatory 
cytokines and chemokines, trophic factors, phagocytosis, and regulated forms of cell 
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death (i.e. apoptosis or pyroptosis) [35, 38, 39]. However, persistent inflammation can 
elicit additional damage, further perpetuating the inflammatory cycle and CNS pathology. 
Neuroinflammation has been reported in several LSDs, although the intensity of 
inflammatory changes and the molecular pathways responsible for triggering 
neuroinflammation in each likely differ. Although LSDs are caused by distinct genetic 
mutations they share some common downstream attributes, the foremost being 
lysosomal storage material accumulation. While the biochemical composition of storage 
material differs between various LSDs, emerging evidence suggests that it can either 
activate or perpetuate neuroinflammation, which can contribute to neuronal death [27]. 
Indeed, recent studies report that an imbalance between the synthesis and degradation 
of sphingolipid intermediates plays a prominent role in eliciting neuroinflammatory 
outcomes [40]. For example, tumor necrosis factor α (TNF-α) can activate 
sphingomyelinase (SMase), a key enzyme responsible for ceramide production, which 
leads to elevated ceramide levels that have been reported in CLN3 disease [41, 42]. It is 
well appreciated that high ceramide concentrations can also perpetuate inflammatory 
cascades such as NF-B activation, trigger inflammasome activation, and disrupt normal 
cellular functions [40, 41]. Ceramide accumulation correlates with decreases in 
sphinosine-1-phosphate (S1P), thereby inducing apoptotic pathways and glial activation 
[40]. The S1P antagonist FTY720 has been shown to attenuate glial activation and 
neuroinflammatory processes, which leads to reduced relapse rates in multiple sclerosis 
[43, 44] and a recent report has demonstrated beneficial effects of FTY720 in a mouse 
model of Sandhoff disease [45]. Glucosylceramide accumulation in Gaucher disease 
(GD), resulting from glucocerebrosidase deficiency, has been shown to augment 
cytokine production in microglia [46]. Likewise, glucocerebrosidase loss in a mouse 
neuropathic model of GD causes microglial activation as early as postnatal day 12 [47]. 
The loss of lysosomal function coupled with lipid inclusion formation disrupts lysosomal 
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membrane integrity, resulting in increased permeability and translocation of lysosomal 
contents into the cytosol [48]. For example, defective  lysosomes release hydrolases, 
metabolites, and cathepsins into the cytoplasm that can be sensed as intracellular 
DAMPs [29]. Cathepsins, in particular cathepsin B, have been shown to trigger NLRP3 
inflammasome activation that contributes to neuroinflammation as well as induces 
neuronal apoptosis [49].  Additional intracellular changes that have been reported in 
various LSDs also have the ability to trigger and/or propagate neuroinflammation. For 
example, several LSDs display elevated intracellular calcium (Ca2+)i levels [50, 51] and 
disruption of Ca2+ homeostasis can induce multiple inflammatory processes in many 
CNS cell types [52]. In the case of microglia, elevated Ca2+i can induce inflammasome 
activity, cytokine release, and NF-κB activation. In neurons, increased Ca2+i disrupts 
synchronized synaptic activity, and dysregulated neuronal firing can augment glutamate 
and ATP release as well as other “danger” signals that, in turn, trigger Ca2+i elevations in 
surrounding glia [53], effectively perpetuating the response. In addition, storage material 
accumulation in LSDs disrupts normal ER function and causes ER stress, eliciting an 
unfolded protein response (UPR), a physiological reaction that halts protein synthesis in 
an effort to correct disrupted protein folding. However, a persistent UPR induces 
apoptosis by activating various signaling cascades, which can have catastrophic effects 
on the CNS [54-56]. Besides inducing cell death, ER stress can also trigger intracellular 
proinflammatory processes [57]. For example, Ca2+i release leads to NF-κB activation 
and subsequent cytokine, chemokine, and ROS production, which can exacerbate 
neuropathology [57, 58]. Additionally, ER stress in astrocytes can trigger the activation of 
surrounding microglia, leading to increased IL-6 production [59]. In the context of CLN3 
disease, cytokine/chemokine production and caspase-1 activation has been shown to be 
exaggerated in Cln3Δex7/8 microglia; however, the impact of neuroinflammation during 
early disease is uncertain, since attempts to detect traditional pro-inflammatory 
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mediators during acute CLN3 pathology in the mouse model have been negative. 
However, our group has found that aberrant caspase-1 is a critical driver of early 
disease pathology (Kielian laboratory, unpublished observations), suggesting that 
caspase-1 may act independently of its traditional role in pro-IL-β processing to cleave 
other proteins implicated in lysosomal biology and cargo trafficking. Neuroinflammation 
is an overarching theme in several LSDs that may propagate neurodegeneration.  
 
Neuronal Ceroid Lipofuscinosis (NCL):  
NCLs are a diverse group of autosomal recessively inherited LSDs caused by a 
mutation in one of 14 different ceroid lipofuscinosis (CLN) genes [7]. To date, 403 
mutations have been associated with the known NCL forms.  NCLs have been estimated 
to collectively occur in 1 out of every 100,000 live births per year [60-65]. There are four 
age-dependent classifications of NCL that correlate with specific genetic mutations; 
namely, infantile (INCL), late infantile (LINCL), juvenile (JNCL), and adult onset [66]. The 
four subtypes generally present with similar symptoms that include visual deterioration, 
neurocognitive and physical decline, seizures, and premature death, although the 
sequence of symptom appearance differs between forms [8, 67-69]. The early onset 
NCLs, including infantile and late infantile, are the most aggressive in terms of the short 
interval from diagnosis to death and are generally typified by more prominent 
neuroinflammatory responses [70]. The various NCL-related mutations result in either a 
loss in lysosomal enzymes, lysosomal transmembrane proteins, or synaptic vesicle-
associated proteins [7]. Although the function of some NCL-related genes are known 
(i.e. CLN1 and CLN2 encode for the lysosomal enzymes PPT-1 and TPP-1, 
respectively), others remain elusive (i.e. CLN3, CLN5, CLN6). Mutations in each of the 
CLN proteins lead to the accumulation of lysosomal storage material whose biochemical 
composition varies according to each disease type. For example, storage material can 
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contain mitochondrial ATP synthase subunit c, sphingolipids, and lipofuscin, the latter of 
which is responsible for the autofluorescent properties of storage material [71, 72]. To 
date there is no cure for any of the NCL forms, only treatments to manage clinical 
symptoms.  
 
Juvenile Neuronal Ceroid Lipofuscinosis (CLN3 disease) 
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also known as juvenile Batten 
disease (CLN3), is the most common form of all the NCLs with an estimated incident of 
2-4 in every 100,000 live births a year [60-62]. Symptom onset presents in patients 
between the ages of 5-10, with rapid visual deterioration caused by aggressive 
retinopathy, macular degeneration, and optic atrophy [73]. Vision loss is followed by 
motor dysfunction, manifesting as Parkinson-like symptoms due to extrapyramidal and 
cerebellar disruptions that progress to quadriplegia [73, 74]. CLN3 patients have severe 
epileptic seizures that become increasingly refractive to treatment. Cognitive 
impairments appear early in the disease, with incontrollable speech patterns that 
progress to early onset dementia and severe dysarthria [75]. Similar to other NCL forms, 
disease pathology mainly affects the CNS [76]. MRI reveals the development of cortical 
lesions in the cerebral cortex along with cortical and hippocampal atrophy [77, 78]. 
However, unlike early onset NCLs, CLN3 disease pathology is protracted, resulting in 
premature death by the late teens -early twenties [79].   
JNCL is caused by autosomal recessive mutations in CLN3. There are currently 
49 mutations that have been discovered in the CLN3 gene, the most common (~85%) 
being a 1.2 kb deletion spanning exons 7 and 8 [60, 73]. This deletion causes a frame 
shift mutation, resulting in a premature stop codon and a truncated form of the protein. 
The truncated CLN3 protein is hypothesized to undergo rapid decay, resulting in the loss 
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of lysosomal function [80, 81]. Lysosomal disruption results in the progressive 
accumulation of storage material primarily composed of autofluorescent ceroid 
lipopigments and mitochondrial ATP synthase subunit C [82]. The fingerprint-like 
inclusion deposits can be visualized by electron microscopy as early as the first trimester 
during development [83, 84]. Unlike other forms of NCL, which have a loss of lysosomal 
enzymes, the CLN3 protein, or battenin, is a 438-amino acid transmembrane protein 
primarily localized to the lysosomal membrane with minor expression reported in the 
endosome [85-87]. Both the CLN3 gene and protein are ubiquitously expressed in all cell 
types; however, the mutation has been found to primarily disrupt cells of neuronal 
lineage [8, 71, 72, 88]. The exact function of CLN3 is unknown; however, to date it has 
been implicated in multiple cellular processes including, lysosomal pH maintenance, cell 
proliferation, apoptosis, autophagy, intracellular trafficking, endocytosis, amino acid 
transport, mitochondrial function, and Ca2+i regulation [86, 89-92]. The lack of high-
quality CLN3-specific antibodies has made it challenging to determine the precise 
function and membrane localization of CLN3 and therefore, researchers have relied on 
overexpression or knockout models to speculate on the role of CLN3 in cellular function 
and disease implications.  
 
Current CLN3 disease models 
To gain a better understanding of the function of CLN3, researchers have 
developed multiple models to investigate the role of CLN3 in JNCL disease pathology 
and progression. One of the earliest models created was utilizing the yeast strain 
Saccharomyces cerevisiae. Yeast are often ideal for studying molecular pathways as 
they are similar to mammalian systems. The yeast genome is easily manipulated and 
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has a short growth cycle, allowing the study of complex molecular systems, such as 
gene function and regulation, protein function and interaction networks, and drug 
discovery using high-throughput library screens [93]. Following whole genome 
sequencing of Saccharomyces cerevisiae, BTN1 was discovered as a human Cln3 
homologue. BTN1 is a non-essential protein that is 59% similar and 39% identical to 
Cln3 [94, 95]. It has been reported that BTN1 deletion disrupts pH homeostasis, leading 
to the formation of large vacuoles with increased intraluminal pH, similar to the 
lysosomal disruption observed in CLN3 disease [96]. Btn1 also plays a significant role in 
phospholipid distribution in the cell membrane, regulation of Golgi apparatus number, 
morphology, and location, as well as cellular metabolism [9, 94, 95, 97-99]. These 
studies suggest a similar function for mammalian Cln3 and a more complex role beyond 
lysosomal function, including intracellular trafficking and amino acid metabolism [97, 98]. 
While the yeast model is useful for studying molecular pathways, it lacks the complex 
system of higher vertebrates that provide greater insights into disease pathology. 
There are currently two murine models utilized in the JNCL field, namely Cln3 
knockout (Cln3-/-) and Cln3 knock-in (Cln3Δex7/8) [100, 101]. The models were created on 
either a C57BL/6 or 12S6/SvEv genetic background, both displaying some phenotypes 
and pathology similar to human patients, such as accumulation lysosomal storage 
material, glial activation, and neuron dysfunction, however the 2 backgrounds are slightly 
different [27, 100-102]. For example, there are significant behavioral differences 
between C57BL/6 or 12S6/SvEv Cln3-/- and Cln3Δex7/8 animals. A comprehensive study 
by Kovacs and Pearce 2014 found that mice on the C57BL/6 background were 
significantly more explorative compared 12S6/SvEv mice, which exhibited anxiety-like 
behavior. It was also discovered that JNCL mice on the12S6/SvEv background had 
more severe motor impairment compared to C57BL6 [103]. At the cellular level, Finn et 
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al (2010) found that neurons cultured from Cln3-/- mice on the C57BL/6 background 
express significantly more NMDA receptor (NR2B), which is likely why these neurons 
are significantly more sensitive to NMDA-mediated excitotoxicity [67]. Therefore, it is 
imperative that the genetic background be taken into account when deciding on the most 
appropriate JNCL mouse model to use for studies. The first mouse model developed 
used targeted disruption genetic techniques to remove the Cln3 start codon and first six 
exons that were replaced with a neo cassette. Cln3-/- mice have been extensively 
characterized and recapitulate many disease attributes found in humans [32, 103-105]. 
Namely, these animals exhibit progressive accumulation of autofluorescent storage 
material, glial activation, neuronal loss, and visual deficits, although the latter two do not 
manifest until relatively late in the disease process (i.e. 12-18 months of age) [32]. While 
Cln3-/- mice are a good model for studying Cln3 function and its role in disease 
pathology, they are unable to fully recapitulate the human disease due to the fact that 
patients do not typically present with a complete disruption of the CLN3 gene. On the 
other hand, the Cln3Δex7/8 mouse model was engineered to harbor the same mutation as 
roughly 85% of JNCL cases, which is a 1.02kb deletion spanning exon 7 and 8 [60]. 
These mice were generated by deleting exons 7 and 8 of the endogenous CLN3 gene 
by homologous recombination, which was replaced with exons 7 and 8 harboring the 
1.02kb CLN3 mutation to create a “knock-in” mutation [100]. Cln3Δex7/8 animals display 
early accumulation of lysosomal storage material along with glial activation, motor 
deficits, disrupted neuronal activity, and a protracted disease time line similar to what is 
seen in CLN3 patients [33, 100, 102, 103, 106]. However, similar to the Cln3-/- model, 
neuronal death is not evident until late stage disease (i.e. 12-18 months). The Cln3Δex7/8 
mouse model has been especially valuable in the discovery and development of novel 
therapeutics for CLN3 disease.  
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Cell-Specific Disease Pathology in CLN3 disease 
Microglia  
Microglia are the principal resident immune cells in the CNS parenchyma, 
accounting for approximately 10% of cells in the brain. Under non-pathological 
conditions, microglia are quiescent and in a constant state of surveillance for stress 
signals i.e. danger-associated molecular patterns (DAMPs) or pathogen-associated 
molecular patterns (PAMPs) [39, 107]. Along with ensuring cellular protection by 
phagocytosing cellular debris or preventing insult to surrounding neurons, microglia are 
also involved in neurodevelopment via synaptic pruning and providing trophic support 
[108, 109]. When microglia sense DAMPs or PAMPs released from damaged or dying 
neurons, reactive astrocytes, or infectious material [110] via Toll-like receptors and other 
pattern recognition receptors [35, 111], they become activated. Once activated microglia 
change both chemically and morphologically by becoming ramified in shape, undergo 
rapid proliferation, and begin to release growth factors, chemokines, and cytokines [112, 
113]. This initial immune response is intended to be neuroprotective, as microglia 
increase phagocytosis to remove cell debris or pathogens as well as secrete 
neurotrophic factors, such as brain-derived growth factor, glia-derived growth factor, and 
nerve growth factor to promote neuronal health [114]. Microglia are a major source of 
chemokines and cytokines that serve to recruit and activate peripheral immune cells, 
respectively, at affected sites [112]. In addition, these mediators can act in an 
autocrine/paracrine manner to activate neighboring microglia, astrocytes, neurons, or 
oligodendrocytes [115, 116]. While intended to be neuroprotective, microglial activation 
is often referred to as a double-edged sword [114]. For example, when inflammation 
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becomes chronic, it often switches from being protective to detrimental as microglia 
continue to release more chemokines, cytokines, amino acids, and reactive oxygen 
species (ROS), which then perpetuate inflammatory mediator release from surrounding 
glial cells, alter target cell function, or induce cell death [117].  Microglial activation is a 
hallmark of virtually all neurodegenerative diseases and is known to play a major role in 
disease pathology and progression [113, 118, 119]. 
It has been suggested that activated microglia may contribute to disease 
progression in JNCL. Activated microglia are evident in the brains of CLN3 patients’ 
post-mortem and JNCL murine models in regions that coincide with eventual 
neurodegeneration [32, 33, 120]. These findings suggest that microglia are responding 
to DAMPs released prior to neurodegeneration; however, the identity of these DAMPs 
and what cell type(s) are releasing these danger signals remains unknown.  There is 
also evidence of increased levels of the pro-inflammatory cytokine IL-1β in JNCL post-
mortem brains; however, this likely reflects secondary inflammation from cellular death 
at end-stage disease, since work from our laboratory has not been able to detect 
significant inflammatory mediator expression in the Cln3Δex7/8 brain during the first 6 
months of life (Kielian lab unpublished observations). IL-1β is an important regulator of 
inflammation in the CNS that activates inflammatory pathways in surrounding glia that 
can create a toxic extracellular milieu if not tightly regulated [121, 122]. Previous work 
from our laboratory found that primary microglia from Cln3Δex7/8 mice exist in a primed 
proinflammatory state [123]. Namely, when exposed to neuronal lysate and C6 ceramide 
to mimic DAMPs associated with disease, numerous proinflammatory cytokines, 
including interleukin-1-beta (IL-1β), TNF-α, interleukin-1-alpha (IL-1α), interleukin-9 (IL-
9), and interleukin-15 (IL-15) were significantly elevated in Cln3Δex7/8 compared to wild 
type (WT) microglia [123]. IL-1β and TNF-α were also shown to augment interleukin-6 
production by Cln3Δex7/8 microglia, and as such the elevated levels of both IL-1β and 
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TNF-α induced by DAMPs could be expected to effectively perpetuate the 
neuroinflammatory circuit [123]. In terms of mechanism, elevated IL-1β production by 
Cln3Δex7/8 microglia was partially regulated by increased caspase-1/inflammasome 
activation, where caspase-1 is the primary enzyme required for processing pro-IL-1β to 
its active form, whereupon it can be secreted [123]. This study also demonstrated 
intrinsic defects in Cln3Δex7/8 neurons, as they were more susceptible to the cytotoxic 
effects of conditioned medium from Cln3Δex7/8 microglia. It is unclear whether diseased 
microglia also produce exaggerated inflammatory mediators in vivo, since we have been 
unable to detect significant pro-inflammatory mediator production in the Cln3Δex7/8 brain. 
However, it is possible that microglial cytokine release does occur but is undetectable in 
brain homogenates due to dilution effects of other CNS cell types. We have identified 
aberrant caspase-1 activity as a critical driver of CLN3 pathology, in that motor deficits 
and glial activation are significantly attenuated in Cln3Δex7/8/caspase-1 KO mice (Kielian 
laboratory, unpublished observations). It is possible that caspase-1 effects are 
independent of its ability to process pro-IL-1β, as the enzyme has been reported to 
cleave over 500 other proteins, many of which impinge on lysosomal function and 
endosomal trafficking that have been identified as pathological mechanisms in JNCL. 
Collectively, these findings suggest that microglial pathology in the context of CLN3 
disease could set the stage for eventual neurodegeneration typical of JNCL. 
 
Astrocytes 
Astrocytes are the most abundant cell type in the brain and are responsible for 
maintaining homeostatic functions in the brain by providing neurotrophic support, 
synchronizing neurotransmitter metabolism and release, and regulating the extracellular 
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milieu [124-126]. The brain is the most energy-demanding organ in the body, yet at the 
same time does not maintain robust energy reserves, thus requiring a tightly regulated 
and uninterrupted nutrient supply. Energy balance is critical for the preservation of ion 
gradients, neurotransmitter production, and neurometabolism [127, 128]. Astrocytes are 
the primary cell that provides neurons with nutrient support required for their normal 
functions[129]. Astrocytes are morphologically structured to monitor the extracellular 
milieu and respond according to cellular requirements to ensure homeostatic functions. 
Astrocytic endfeet surround the intracerebral blood vessels that express glucose 
transporters and aquaporins to shuttle nutrients and regulate osmotic balance, 
respectively, across the blood-brain barrier [130, 131]. Glucose is the primary carbon 
source for the generation of key metabolites, including lactate, pyruvate, glutamate, and 
glutamine [132]. Astrocytes take up glucose, which is then utilized by glycolytic pathways 
to generate lactate. Lactate is released into the extracellular space where it is actively 
internalized by neurons via membrane-associated lactate shuttles. It has been found that 
neurons are capable of oxidizing both glucose and lactate for energy; however, neurons 
preferentially utilize lactate as an oxidative substrate because the cells are able to 
produce higher amounts of ATP via oxidative respiration as opposed to glycolysis [129, 
133].  
Along with monitoring and supplying metabolites to the brain, astrocytes regulate 
neuronal function. Astrocytes project fine processes to ensheath synapses to regulate 
synaptic firing, control neurotransmitter concentrations, and synapse development. A 
single astrocyte process is able to encompass and regulate 300-600 neuronal dendrites 
that may contain thousands of synapses [134, 135]. Astrocytes respond to neuronal 
activity through a cadre of membrane-associated receptors for neurotransmitters, 
cytokines, and growth factors at the tripartite synapse [129]. Astrocytes relay information 
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from neurons to surrounding astrocytes via Ca2+ signaling through gap junctions, 
hemichannels, and other receptors creating a second level signaling network in the 
brain. This network is critical for maintaining neuronal homeostasis and neuronal 
signaling networks.  
One of the most well studied and important astrocyte homeostatic functions is the 
transport and recycling of glutamate, the primary neurotransmitter in the CNS [136-138]. 
Once released from neuronal synapses, glutamate is quickly removed from the synaptic 
cleft via sodium-dependent glutamate transporters present on astrocyte processes at the 
tripartite synapse. Excitatory amino acid transporters 1 and 2 (EAAT 1 and EAAT 2) are 
high-affinity transporters driven by sodium and potassium gradients [139]. Transporter 
activity is an energy-demanding process, as three ATP are required for the removal of 
one glutamate molecule [140, 141]. Once in the astrocyte, glutamate is metabolized via 
one of two pathways based on the needs of the surrounding cells and extracellular 
glutamate concentrations [142]. First, glutamate can enter the TCA cycle to be converted 
to α-ketoglutarate, which can then be utilized to produce nutrients or energy metabolites 
such as lactate that is released back into the extracellular milieu for neurons [136]. 
Second, glutamate can be converted to glutamine by the enzyme glutamine synthetase. 
Glutamine is then released from astrocytes, whereupon it can be internalized by neurons 
through SAT transporters [143, 144]. Neurons then convert glutamine back into 
glutamate to be packaged into synaptic vesicles for neurotransmission. Astrocytes are 
the primary cell responsible for recycling and restoring glutamate in the brain [129]. 
Astrocytes not only regulate glutamate trafficking but are also capable of producing 
glutamate de novo if needed via glucose metabolism [145]. If any step in the glutamate-
glutamine cycle is disrupted, this causes glutamate accumulation in the synaptic cleft, 
which often induces neuroexcitotoxicity and subsequent neurodegeneration. Glutamate 
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dysfunction has been reported in a multitude of neurodegenerative diseases, including 
PD, AD, epilepsy, and JNCL [104, 146-148].   
Besides these critical homeostatic functions, astrocytes also participate in 
neuroinflammatory responses through their robust secretion of various chemokines [149, 
150]. Upon activation, astrocytes undergo a morphological transformation typified by 
increased intermediate filament expression (i.e. glial fibrillary acidic protein (GFAP) and 
vimentin) and reactive astrocytes have been implicated in the pathogenesis of various 
neurodegenerative diseases [146-148]. For example, astrocytes with mutations in 
superoxide dismutatse-1 (SOD-1), a mutation responsible for some forms of 
amyotrophic lateral sclerosis, release soluble toxins that specifically kill motor neurons 
through Bax-dependent mechanisms [151]. Reactive astrocytes can also release 
lipocalin 2, a gelatinase-associated lipocalin, which is upregulated in frontotemporal lobe 
dementia patients and selectively toxic to neurons [152]. In addition, astrocyte activation 
often compromises glutamate homeostatic pathways, such as glutamate uptake and 
recycling mediated by glutamate transporters and glutamine synthetase, respectively 
[39, 147]. Astrogliosis has even been found to change the expression and function of 
neuronal proteins [153]. In the case of a glial-induced seizure model, activated 
astrocytes disrupted NKCC1 and KCC2 chloride channels in neurons, which impaired 
GABAergic inhibition and increased extracellular glutamate levels [154]. Reactive 
astrocytes have been detected during the acute phase of disease in animal models of 
AD, PD, and several LSDs, likely setting the stage for neuronal dysfunction and 
neurodegeneration [36, 39, 47, 155]. In response to insult or injury, reactive astrocytes 
have been shown to provide a bordering function to isolate areas of damage by forming 
a “glial scar” that prevents dying cells from impacting healthy tissue. Neuroinflammation 
also elicits astrocyte hemichannel opening concomitant with reduced gap junction 
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activity, which together can significantly disrupt neurotransmitter regulation [156, 157]. 
However, chronic neuroinflammation can also impair astrocyte neurotrophic support, 
making neurons more vulnerable to cytotoxic events [36]. 
Along with reactive microglia, astrocytosis has been observed in the brain of 
CLN3 patients’ post-mortem in addition to CLN3 mouse models [32, 33, 102, 120]. 
Activated astrocytes have been found in multiple brain regions early in disease 
progression. These same areas are eventually associated with modest signs of 
neurodegeneration in CLN3 mouse models, namely the thalamus and somatosensory 
barrel field cortex [32, 33]. Early gliosis is likely an indicator of neuronal distress; 
however, this remains to be definitively demonstrated. Work from our group supports 
early neuronal dysfunction in the Cln3Δex7/8 mouse model, where synaptic activity was 
significantly heightened in the Cln3Δex7/8 brain from 1-4 months of age compared to WT 
animals [158]. The functional implications of reactive glia in CLN3 disease progression 
remains unclear and can be envisioned to be either a protective response to cellular 
stress or detrimental, leading to the loss of critical CNS homeostatic functions.  
Previously our lab has reported that astrocytes display increased hemichannel activity 
coupled with decreased expression of gap junction proteins [159]. Increased 
hemichannel activity can cause the release of a multitude of small hydrophilic molecules 
from the cytoplasm, including Ca2+, ATP, and glutamate [160]. All three of these 
molecules are capable of influencing neuronal activity. Astrocytes rely on hemichannels 
and gap junctions to communicate with surrounding cells and to respond to the 
extracellular milieu. Aberrant hemichannel activity in the context of CLN3 mutation 
suggests a disruption or loss of astrocyte communication networks and thus the inability 
to regulate neuronal functions in JNCL. Coupled with the disruption of astrocyte 
signaling networks, our laboratory discovered that JNCL astrocytes have reduced 
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expression of glutamate transporter EAAT 1 and glutamine synthetase in multiple brain 
regions [159]. Without these critical proteins, JNCL astrocytes are ill-equipped to remove 
excess glutamate from the synapse or regulate neuron synaptic activity, thus potentially 
setting the stage for the vicious cycle of neuroexcitotoxicity characteristic of CLN3 
disease. 
Neurons 
  Neurons are highly specialized cells within the CNS that are responsible for 
regulating virtually all human functions and comprise roughly 10% of the cells in the 
brain [161]. There are multiple types of neurons, each with highly specific functions 
based on morphology, location within the brain, and connection to neuronal circuits 
[162]. Neurons influence brain activity through complex neuronal signaling networks. 
Neurons extend axons and dendrites to form synapses that are utilized to interpret and 
respond to external signals via electrical signaling. These signals are propagated 
primarily through excitatory (glutamate) and inhibitory (GABA) neurotransmitters 
released from the pre-synaptic neuron into the synaptic cleft [163]. These 
neurotransmitters bind to receptors (i.e. NMDA, AMPA, or metabotropic receptors; 
mGluR1-8 for glutamate and GABAA and GABAB for GABA) on the post-synaptic 
neuronal membrane and the message is transmitted [136]. The development of neuronal 
signaling circuits, their maintenance, and processing are tightly regulated and highly 
vulnerable to damage. Therefore, it is imperative to maintain neuronal homeostasis to 
hold neurodegenerative processes at bay.       
Similar to several other LSDs, CLN3 disease mainly exhibits neuropathological 
manifestations [6, 7, 47, 164, 165]. While the CLN3 mutation is present in all cell types 
throughout the body, neurons are the most dramatically affected. Lysosomal inclusions 
begin to accumulate early in neurons, where our laboratory and others have observed 
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neuronal inclusions as early as postnatal day 30 in Cln3Δex7/8 mice, which precedes 
neurodegeneration [158, 159]. Even though lysosomal dysfunction appears early in the 
disease, neuronal loss does not become apparent in murine models until approximately 
12-18 months [32, 33]. Likewise, neurological symptoms in humans do not present until 
around 10-15 years of age [73]. This implies the existence of compensatory mechanisms 
to maintain homeostasis until a pathological threshold is reached. Since lysosomal 
inclusions occur early in the disease process, this is a disconnect from neuronal death 
that is delayed in comparison and suggests that neuronal loss does not result from 
lysosomal inclusions. In addition, some neurons harbor large lysosomal inclusion 
burdens, yet are not lost during the disease process. Another interesting finding is that 
neurodegeneration in JNCL is localized to thalamocortical, cerebral cortex, and 
cerebellum regions for reasons that remain unclear [32, 33]. One popular view point is 
that neurodegeneration results, in part, from glutamate excitotoxicity. Elevated levels of 
glutamate have been found in the cortex and cerebellum of Cln3-/- mice [104]. In 
addition, inhibitory neurons are more impacted than excitatory neurons, which has been 
attributed to increased GAD65 auto-antibody production [166]. GAD65 is a glutamic acid 
decarboxylase that converts glutamate to GABA and the loss of inhibitory neurons leads 
to unregulated excitatory synaptic activity causing a rise in glutamate release [167].  As 
previously described, glutamate transporter and glutamine synthetase expression are 
significantly decreased in Cln3Δex7/8 astrocytes, which would render them ill-equipped to 
regulate increased levels of glutamate release [159]. In turn, elevated extracellular 
glutamate triggers continuous neuronal firing that further perpetuates glutamate release, 
which can eventually culminate in neuroexcitotoxicity. Our laboratory has recently 
identified supportive evidence for neuronal hyperexcitability during early CLN3 disease. 
Electrophysiology analysis revealed that axonal excitability was significantly enhanced in 
Cln3Δex7/8 neurons in the hippocampus and visual cortex at 1 month of age compared to 
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WT animals [158]. This represents the first evidence of early neuronal dysfunction that 
may lead to detrimental effects as the disease progresses. Cln3Δex7/8 axonal excitability 
diminished by 12 months of age and was associated with delayed signal propagation in 
axonal fibers [158]. This late neuronal phenotype has also been described in other forms 
of NCL. For example, in the Ppt1-/- and Cln6-/- mouse models of infantile Neuronal Ceroid 
Lipofuscinosis (INCL), changes in axonal and synaptic proteins are observed during at 
one month of age that precede the onset of pathology [168].  Collectively, this data 
indicates that neurons are the ideal and primary target for novel therapeutic 
interventions. 
 
Current JNCL Therapeutics 
Although our understanding of LSDs has significantly expanded since the 
discovery of the lysosome by DeDuve in the 1950s, many questions remain 
unanswered. There is currently no cure for any of the LSDs including JNCL, and the only 
available therapeutics target disease symptoms and provide palliative care for patients. 
Therefore, it is imperative to identify novel therapeutics to not only alleviate symptoms 
but also slow disease progression and extend life expectancy. The genetic mutations 
unique to each LSD result in distinct malfunctions of a specific lysosomal mechanism 
[56, 86, 169-171]. However, as previously mentioned, a common thread between all 
LSDs is the role of neuroinflammation in disease development and progression making 
the pathway an enticing target which could benefit multiple LSD [172]. One such 
potential drug is Mycophenolate mofetil (CellCept, which is a FDA-approved 
immunosuppressant used to prevent transplant rejection by inhibiting T cell and B cell 
expansion [173-175]. Murine studies in Cln3-/- mice found that CellCept reduced glial 
activation, decreased circulating GAD65 autoantibody, and improved motor function 
[176]. A phase 1/2 clinical trial was conducted on JNCL patients and found that CellCept 
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had some benefit in delaying vision loss (although this was a case report of a single 
CLN3 patient), it did not delay disease progression [177]. Many of the mutations that 
cause NCL affect other lysosomal enzymes, such as PPT1 and TTP1. For those NCLs 
that are caused by the lack of enzymatic activity, current therapeutic approaches include 
enzyme replacement therapy, which is costly and presents many challenges to achieve 
therapeutic enzyme levels in the brain because the blood-brain barrier remains intact in 
many instances [178].   
Just as the brain is a complex system, the process of neurodegeneration in JNCL 
is multifactorial. Many studies have been working to identify novel therapeutic targets 
that could impact multiple pathways and cell types. One such target is the regulation of 
cyclic adenosine monophosphate (cAMP) production. cAMP is a second messenger that 
translates extracellular cues to affect intracellular signaling cascades [179]. cAMP 
production is initiated by activation of transmembrane G-protein coupled receptors that 
sequentially activate membrane bound adenylyl cyclases to convert ATP to cAMP [180]. 
cAMP then activates protein kinase A which phosphorylates several proteins [181]. 
cAMP has been implicated to play a role in multiple cellular pathways, including neuronal 
plasticity and memory, immune regulation, and maintaining neuronal homeostasis [182-
184]. cAMP is able to tailor responses based on concentration levels, duration of cAMP 
production, and target cell type [179].  Reductions in cAMP levels have been found in 
multiple neurodegenerative diseases, including AD and traumatic brain injury coupled 
with increased microglial activation and disrupted neuronal synaptic activity [185-187]. 
cAMP is regulated by cyclic nucleotide phosphodiesterases (PDEs). There are 11 PDE 
families (PDE1-11) that are further divided based on function. For example, PDEs 5, 6, 
and 9 hydrolyze cyclic guanosine monophosphate (cGMP), whereas PDEs 4, 7, and 8 
specifically hydrolyze cAMP. PDE4 is the most abundant isoform in the CNS [179, 188]. 
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There are 21 genes that encode for the PDE superfamily and through splice variations 
approximately 100 PDE proteins are generated [179, 189]. Dysregulation or reduction in 
cAMP levels can have detrimental effects in the CNS, which has been demonstrated 
with the use of various PDE4 inhibitors to augment cAMP levels. For example, Gong et 
al (2017) found that rolipram, a FDA-approved PDE4 inhibitor, increased synaptic 
plasticity and improved learning and memory, and reduced amyloid-β aggregations in 
APP/PS1, an AD mouse model. Rolipram had a positive effect on learned behavior (i.e. 
fear conditioning) within 30 min of treatment with effects persisting well beyond 
treatment cessation, indicating that PDE4 inhibition can reverse disease pathology and 
improve cellular function [190]. Due to the success of PDE4 inhibitors in various 
neurodegenerative diseases, our laboratory tested the efficacy of three chemically 
distinct PDE4 inhibitors in Cln3Δex7/8 mouse model of JNCL. It was hypothesized that 
PED4 inhibitors would affect multiple disrupted pathways in JNCL, such as, glial 
activation, neuronal function, and glutamate regulation. All three PED4 inhibitors tested 
led to significant improvements in lysosomal function, increased glutamate transporter 
expression, reduced glia activation, and improved motor behavior in Cln3Δex7/8 mice. 
Additional details from this study will be discussed in Chapter 4.  
Gene therapy 
Significant progress has been made in the development and preclinical testing of 
gene therapy in a wide array of neurodegenerative diseases, including AD, spinal 
muscular atrophy, Rett syndrome, and LSDs [191-195]. Following the pioneering 
discovery that viruses possessed the ability to transfer genes, multiple types of viruses 
have been used for therapeutic studies, including retroviruses and adeno-associated 
viruses (AAV) each with differing benefits.  Retroviruses are RNA viruses that reverse 
transcribe their genome into double stranded DNA (dsDNA) that is integrated into the 
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host cell genome [196, 197]. Retroviruses are easily manipulated to allow for a broad 
range of target cell specificity. This can be achieved by altering the envelop proteins on 
the viral surface. Because integration of the retrovirus genome into host cells is 
imperative for viral survival, transduction leads to stable genetic modification, which is 
then capable of being passed on to progeny cells in the case of stem cells [198].  Many 
different types of envelop proteins have been utilized for CNS transduction, including 
vesicular stomatitis glycoprotein, VSV-G and Mokola viral envelopes, and HIV gp41 
glycoprotein, all of which provide unique and specific neuronal transduction [199]. 
However, the caveat of using retroviruses is there is a potential for the immune system 
to respond against the transgene as well as possible off-target integration that could 
disrupt normal genes [197].  
Relatively new to the field of gene therapy yet extensively utilized, are AAV 
vectors that are small single-stranded DNA (ssDNA) non-enveloped viruses that can 
only replicate with “helper” adenoviruses due to the fact that they are replication 
incompetent [200]. There are currently nine known serotypes of AAV (AAV1-9), each 
with their own tissue-specific properties. AAV2 was the first serotype discovered with 
broad tissue tropism that provided the basis for future AAV vector development [201]. 
For example, AAV8 has high tropism for the liver and is currently undergoing clinical 
trials to treat hemophilia B [202]. AAV9 is capable of traversing the blood-brain barrier 
(BBB) following i.v. injection to target the CNS through mechanisms that are currently 
not fully understood [203-205]. Utilizing the 37/67-kDA laminin receptor to gain cell entry, 
AAV9 preferentially targets neurons and astrocytes in brain of both neonatal and adult 
mice [204, 206]. Recombinant AAV (rAAV) vectors do not contain viral genes nor 
integrate into the host genome; therefore, eliminating previous concerns of activating 
inflammatory pathways by RNA intermediates or disrupting normal gene functions 
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caused by retroviruses [207]. However, because the AAV genome is not able to 
integrate into the host DNA, transgenes are lost during cell division. While rAAVs appear 
to be ideal candidates for gene therapy, there are multiple limitations, including the rate-
limiting steps of converting ssDNA into dsDNA prior to gene expression, and genome 
instability and expression following conversion [208]. This can be bypassed by using 
self-complimentary AAV (scAAV) vectors. scAAV is a ssDNA construct that contains 
palindromic inverted terminal repeats that cause the ssDNA to fold into a hairpin loop 
forming dsDNA. The repeats are the replication origins for DNA polymerase to 
synthesize complementary strands [209]. The scAAV dsDNA packaging significantly 
increases viral efficiency, speed of transduction, as well as increase stable protein 
expression that is capable of persisting for up to 10 years in the human brain following a 
single injection [210]. The only drawback to scAAV is that the viral DNA packaging 
capacity is reduced from 4.7 to 2.5 kb; however scAAVs are 600-fold more efficient at 
transduction than ssAAV vectors [209].  
Many studies testing the utility of gene therapy are currently ongoing for NCLs. 
Infantile (CLN1) and Late Infantile (CLN2) Neuronal Ceroid Lipofuscinosis mutations 
lead to a loss of the soluble lysosomal-specific enzymes, PPT1 and tripeptidyle 
peptidase 1 (TPP1), respectively [80]. PPT1 catalyzes the cleavage of thioester bonds 
between fatty acids and TPP1 is a serine protease that removes tripeptides from amino 
termini of proteins as well having endopeptidase activity; however, the precise 
substrates in vivo have not yet been defined [211, 212]. Both PPT1 and TPP1 are 
secreted from cells during lysosomal exocytosis and can internalized surrounding cells 
via mannose-6-receptor-mediated endocytosis, allowing for cross-correction to occur. 
This is adventageous for CLN1 and CLN2 gene therapy because it does not require high 
CNS transduction efficiencies to achieve therapeutic benefit. For example, Passini et al 
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(2006) performed intracranial injections of an AAV2 vector harboring human CLN2 into 
the hippocampus, thalamus, and cerebellum of 6-week-old CLN2 KO mice and studied 
effects on disease progression for 6 – 13 weeks post-injection [213]. Although TPP1 
enzyme activity was only increased proximal to the injection site, significant reductions in 
lysosomal inclusions were observed in the ipsilateral hemisphere [213]. Similarly, 
Haskell et al (2003) discovered that following a single intracranial injection of AAV5-
CLN2 there were very few TPP1+ cells; however, over a 10 day to 16-week period TPP1 
activity gradually increased, suggesting TPP1 cross-correction [214]. Unfortunately, 
JNCL cannot benefit from cross-correction, since CLN3 encodes a transmembrane 
protein that is not secreted [197, 215]. Therefore, only cells that are successfully 
transduced with a particular virus will be affected. Nevertheless, this has not deterred 
researchers from developing and testing gene therapy, since prior work with sheep 
chimeric for CLN5, another lysosomal transmembrane protein did not display overt 
disease symptoms, suggesting that not all cells need to be corrected to achieve clinical 
benefit.   
Since CLN3 is a transmembrane protein whose protein expression is maintained 
at low but constant levels throughout life and loss of CLN3 results in primarily 
neurological symptoms, there are certain criteria that need to be satisfied when 
considering gene therapy approaches [73-76, 216]. First and most importantly, the viral 
vector needs to transduce cells in the CNS, which has been well documented for AAV2, 
AAVrh.10, and AAV9 [217]. Secondly, transgene expression must remain stable for a 
long period of time because multiple injections are neither necessarily practical nor 
feasible for clinical trials because of the generation of anti-AAV antibodies [218]. It is 
also likely important that CLN3 protein levels mimic endogenous expression, since over-
expression could lead to toxicity as has been reported in the yeast model of CLN3 and 
27 
 
too low of expression may have no effect. Utilizing AAVrh.10 containing human CLN3, 
Sondhi et al (2012) injected 3x103 viral genomes directly into the hippocampus, 
cerebellum, and striatum of neonatal Cln3Δex7/8 mice[219]. Sixteen to eighteen months 
post-injection, Cln3Δex7/8 mice displayed hCLN3 expression in these brain regions along 
with significant reductions in lysosomal inclusions, suggesting improved lysosomal 
function [219]. However, hCLN3 expression was only found in close proximity to the 
injection site and did not disseminate. The virus was also only able to reduce 
astrocytosis with no effect on microglial activation or preventing neurodegeneration. 
These results indicate that it is possible to utilize gene therapy to replace a lysosomal 
transmembrane protein; however, the experiment fell short in reversing or slowing JNCL 
disease progression [219]. Recently our laboratory developed a novel JNCL gene 
therapy approach utilizing scAAV9 harboring hCLN3 driven by two distinct promoters 
(chicken β-actin and mouse MeCP2) that have different cell specificity and expression 
levels to determine the most appropriate level of CLN3 required for homeostasis, as well 
as, determine if neurons or astrocytes would benefit more from CLN3 expression. One 
month-old Cln3Δex7/8 mice were given a single i.v. injection of each promoter construct to 
replicate onset of JNCL disease symptoms and the most therapeutically relevant route of 
injection. The scAAV9-MeCP2-hCLN3 construct was able to significantly improve 
lysosomal pathology, glial activation, and motor behavior in Cln3Δex7/8 mice, which will be 
further discussed in Chapter 5.  
 
Overview of Dissertation 
 This dissertation describes two major focus areas in our laboratory; 
namely, elucidating underling mechanisms that cause JNCL pathology (role of astrocyte 
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glutamate regulation, mitochondrial dysfunction, and Ca2+ signaling activity) and the 
development of novel therapeutics to slow disease progression and improve the lives of 
children afflicted with JNCL. Prior work from our laboratory identified reactive astrocytes 
in Cln3Δex7/8 mice at postnatal day 90 coupled with reduced expression of the glutamate 
transporter GLAST and glutamine synthetase, key regulators in the glutamate-glutamine 
pathway. Cln3Δex7/8 astrocytes also exhibited aberrant hemichannel activity and 
reductions in hemichannel protein expression. These results indicate a disruption in 
astrocyte homeostasis and a potential loss of neuronal support. Currently there is very 
little known about the role of astrocytes in JNCL. My research examined changes in 
mitochondrial function and Ca2+ signaling in Cln3Δex7/8 astrocytes, two pathways that can 
contribute to neuronal excitotoxicity in JNCL.  
There is currently no cure for JNCL making it imperative to find novel 
therapeutics to improve and prolong patient survival. Previous studies of several mouse 
neurodegenerative disease models have found positive results with PDE4 inhibitors. 
PDE4 inhibitors were considered to be an ideal drug candidate for JNCL due to their 
ability to affect the pathological cellular triad in the diseased CNS, namely neuronal, 
astrocyte, and microglial dysfunction. Originally PED4 inhibitors were envisioned to 
impact neuroinflammation in JNCL to promote neuroprotection. However, after further 
investigation, our results suggest that the primary mode of PED4 inhibitor action is on 
neuronal activity and neuroprotection that consequently leads to reduced glial activation 
and enhanced glutamate transporter expression.   
 While PDE4 inhibitors were able to reduce disease pathology and improve motor 
function, this approach does not correct the root of the disease, which is the loss of 
CLN3 protein. Utilizing scAAV9 gene therapy, our laboratory was the first to successfully 
transduce the CNS of Cln3Δex7/8 mice with hCLN3 following a single i.v. injection. This 
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study answered multiple important questions concerning gene therapy for JNCL, 
namely, 1) what is the efficacy, tropism, and longevity of scAAV9 following a single 
intravenous injection; 2) what is the ideal expression level of CLN3 for gene therapy; and 
3) are there benefits to targeting specific cell types during CNS gene therapy. Our study 
found that a single i.v. dose of scAAV9-MeCP2-hCLN3 delivered to one month-old 
Cln3Δex7/8 mice was able to transduce cells throughout the brain, spinal cord, and eye. It 
was also determined that low CLN3 protein expression levels were more efficacious in 
reversing disease pathology then higher expression. Finally, our study found that mice 
transduced with hCLN3 controlled by a neuron-specific promoter (i.e. MeCP2) had 
significantly reduced glial activation, less lysosomal pathology, and improved motor 
coordination. Collectively, these results indicate that neurons in JNCL exert a greater 
impact on disease progression then previously hypothesized neuroinflammation induced 
by early glial activation.   
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Chapter 2: Materials and Methods 
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1) Mice.  
The studies described in this dissertation were conducted in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee of the University of Nebraska Medical Center (Approval ID: 11-074-
08-EP). Male Cln3Δex7/8 “knock-in” mice (C57BL/6 background) were used throughout 
these studies, which harbor the same 1.02 kb deletion in CLN3 that occurs in 
approximately 85% of mutated CLN3 alleles[100]. Age-matched male C57BL/6 mice 
were used as WT controls.  
2) Astrocyte and neuron cultures.  
Primary WT and Cln3Δex7/8 astrocytes were prepared as previously described (Esen et al 
2007). Briefly, whole brains were dissected from pups euthanized with an overdose of 
inhaled isoflurane at postnatal day 2-3. Following removal of the cerebellum, the cortex 
was disassociated with trypsin and plated in 75mm2 flasks (one brain per flask). Cells 
were grown in DMEM (4.5 g/L glucose; Hyclone) supplemented with 10% FBS (Atlanta 
Biological), 200µM L-glutamine (Corning), oxaloacetic acid/sodium pyruvate/insulin (OPI; 
Sigma), 1X penicillin/streptomycin/fungizone (Corning), and 100µM L-leucine methyl 
ester (L-LME; Sigma) to induce microglial apoptosis and prevent their expansion. Upon 
reaching confluence (approximately 7-10 days in vitro; DIV), astrocytes were passaged 
every 3-4 days and were not used for experiments past three passages (DIV 30-40). To 
ensure the removal of residual loosely adherent microglia, flasks were shaken at 200 
rpm for 12 h prior to plating. 
 Primary cultures of WT and Cln3Δex7/8 neurons were prepared as previously 
described [123]. Briefly, whole cortices were dissected from E16 embryos and following 
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trypsin disassociation, cells were plated on polyethyleneimine (PEI)-coated 10mm2 
dishes at 106 cells/dish. Medium was changed 4 h after plating to remove non-adherent 
cells. Neurons were grown in Neurobasal medium (Life Technologies) supplemented 
with L-glutamine, penicillin/streptomycin/fungizone (Corning), and B-27 supplement 
(Life). Cultures were treated with 1 µM AraC to prevent glial expansion beginning on DIV 
3 and continuing until use in experiments. Every three days, half of the spent culture 
medium was replaced with fresh medium and cultures were not utilized until after DIV 
10. 
3) Seahorse mitochondrial stress test and glycolysis assays.  
Primary WT and Cln3Δex7/8 astrocytes were plated at 2x104 cells per well in 96-well 
plates. Cells were incubated for 12 h prior to treatment with combinations of TNF-α and 
IL-1β (10ng/ml each) or 5μM C6 ceramide and neuronal lysate (1:5 dilution) for 24 h. 
Neuronal lysate was prepared from primary mouse E16 neurons after multiple freeze-
thaw cycles as previously described [123]. Prior to the start of metabolic assays, culture 
medium was replaced with sodium bicarbonate- and serum-free medium. Mitochondrial 
stress and glycolysis protocols were performed according to the manufacturer’s 
instructions (Seahorse Biosciences). For mitochondrial stress tests, astrocyte oxygen 
consumption rate (OCR) was measured following exposure to sequential injections of 
oligomycin (1μM), FCCP (2μM), and rotenone (1μM). To measure astrocyte glycolytic 
activity, cells were incubated in sodium bicarbonate-, serum-, and glucose-free medium 
for 1 h prior to initiating the assay to reduce astrocyte intracellular glucose stores. Next, 
glucose (2.5M), oligomycin (1μM), and 2-deoxy-D-glucose (100μM) were sequentially 
injected into the wells and extracellular acidification rate (ECAR) was measured. LDH 
release was measured in each well following Seahorse assays to confirm lack of cell 
toxicity. 
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4) Mitochondrial quantification.  
Primary WT and Cln3Δex7/8 astrocytes were plated on 18mm 0.25mg/mL poly-L-lysine 
coated glass coverslips (2x104 cells per coverslip) and incubated for 24 h prior to 
staining with Mitotracker Red CMXRos (1μM; ThermoFisher) to visualize mitochondria. 
Cell Mask Green (ThermoFisher) was added to demarcate the cytoplasm. Immediately 
following staining, astrocytes were washed extensively with culture medium and fixed 
with 4% paraformaldehyde at 37°C for 10 min. Coverslips were mounted using Prolong 
Gold Anti-fade mounting reagent (Life Technologies) and sealed using nail polish. Z-
stack images of single astrocytes were acquired using a Zeiss LSM710 confocal 
microscope. Mitochondria were quantified using the spot function application in Imaris 
(Bitplane; Zurich, Switzerland) and three-dimensional reconstructions of mitochondrial 
staining in astrocytes were generated.  
5) Calcium signaling.  
Primary WT and Cln3Δex7/8 neurons and astrocytes were prepared as described above 
and plated on non-coated 18mm glass coverslips. Cells were loaded with the Ca2+ 
indicator dye Fluo4-AM (1µM) for 30 min. Prior to staining, cells were washed and 
continuously perfused with artificial cerebral spinal fluid (ACSF) during the imaging 
period using AxioVision software (Zeiss; Jena, Germany). For neurons, live cell imaging 
was performed for 1 min to acquire baseline fluorescence signals, whereupon cells were 
stimulated with 25nM glutamate and images were captured every 5 sec for 10 min. For 
neurons, three dishes per experimental group were imaged (7-10 neurons per dish) and 
the experiment was replicated three times. For astrocytes, spontaneous Ca2+ oscillations 
with or without cytokine exposure (TNF-α and IL-1β; 10ng/ml each) for 24 h were 
measured over a 5 min period with images taken every 5 sec for baseline 
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measurements. Astrocytes were then stimulated with 10mM glutamate and intracellular 
Ca2+ signaling associated with the cell soma was quantitated by changes in mean 
fluorescent intensity after normalization to baseline values. Three dishes per 
experimental group were imaged (20 astrocytes per dish) and the experiment was 
replicated 3-4 times. 
6) Glutamate uptake assay.  
Primary WT and Cln3Δex7/8 astrocytes were seeded at 2x104 cells per well in 96-well 
plates. Cells were incubated for 12 h prior to stimulation with TNF-α and IL-1β (both at 
10ng/ml), C6 ceramide (5μM), or neuronal lysate (1:5 dilution) alone or in combination. 
To examine glutamate uptake efficiency, astrocytes were treated with 1mM glutamic acid 
in phenol red-free medium, whereupon supernatants were collected 30 min and 2 h 
later. Glutamate concentrations were immediately analyzed using an Amplex Red 
Glutamic Acid Assay kit according to manufacturer’s instructions (ThermoFisher) with 
values normalized to the respective 1mM glutamate control at each time point. 
7) PDE4 inhibitor treatment.  
The PDE4 inhibitor rolipram (Sigma-Aldrich, St. Louis, MO) was reconstituted in DMSO 
and working stocks for s.c. injections were made weekly in sterile PBS. Based on 
studies of rolipram pharmacokinetics (PK)[220], doses of 0.5 and 5 mg/kg/day were 
selected for proof-of-principle studies in Cln3Δex7/8 mice. A dose of 0.5 mg/kg was 
calculated to yield a concentration of around 68 nM in the brain 1 h after administration 
with a half-life of 1-3 h. By extension, 5 mg/kg was expected to increase CNS doses 10-
fold (i.e. ~ 680 mM). The FDA approved PDE4 inhibitor roflumilast (DalirespTM) was 
provided by AstraZeneca (Wilmington, DE) and was tested at oral doses of 2.5, 5, and 
10 mg/kg/day in Cln3Δex7/8 mice. A roflumilast stock solution was prepared by dissolving 
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in PEG400 (Sigma-Aldrich, St. Louis, MO) and working stocks for oral gavage were 
made weekly by diluting in Methocel E15 (Dow Chemical Inc., Midland, MI). Based on 
the PK properties of roflumilast following oral delivery[221, 222], the highest dose of 10 
mg/kg would lead to a concentration around 50 nM in the brain 1 h after treatment with a 
half-life of 1-4 h, although it’s active metabolite, roflumilast-N-oxide, extends drug action 
to 8 h. Of note, the half-life of roflumilast is much longer in humans (18 h), making it 
amenable to once daily dosing[221, 222]. The PDE4 inhibitor PF-06266047 (ABI-4) was 
provided by Pfizer (Boston, MA) and evaluated at oral doses of 0.5 and 1 mg/kg/day in 
Cln3Δex7/8 mice. A working solution of PF-06266047 for oral gavage was prepared weekly 
by directly dissolving in Methocel A4M (Dow Chemical Inc., Midland, MI). Based on the 
PK properties of PF-06266047, the highest dose of 1 mg/kg would lead to a 
concentration of around 400 nM (total) in the brain 1 h after administration with a half-life 
of 7.5 h[223]. Importantly, because therapeutic levels of PF-06266047 would persist in 
the brain for nearly 24 h with 1 mg/kg dosing, a lower dose of 0.5 mg/kg was also 
examined, which equated to an approximate concentration of 200 nM (total) in the brain 
1 h after treatment. In terms of selectively, rolipram, roflumilast, and PF-06266047 are 
specific inhibitors of all PDE4 isoforms (PDE4A-D) in rodents and do not affect the 
function of any other PDE isoenzymes[221, 222]. In addition, PF-06266047 had no 
activity at 10 µM in greater than 100 off-targets (which exceeds the highest dose 
examined in our study by ~ 100-fold; Patent Number, US 20140235612). Several 
concentrations of each PDE4 inhibitor were examined to identify the minimal 
effective dose that could be considered for potential clinical use. Since roflumilast is 
currently available in oral tablet form and several preclinical studies with other PDE4 
inhibitors have utilized oral delivery24, 25, roflumilast and PF-06266047 were 
adminstered via oral gavage to most closely model the mode of therapeutic delivery 
in CLN3 patients. 
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 Experiments were performed using the National Institute of Neurological Disorders 
and Stroke (NINDS) recommended guidelines to ensure the rigor of these preclinical 
studies[224]. Briefly, age-matched male Cln3Δex7/8 and C57BL/6 WT mice were 
randomized into treatment groups (WT vehicle, Cln3Δex7/8 vehicle, WT PDE4 inhibitor, 
and Cln3Δex7/8 PDE4 inhibitor (n=8/group) and assigned numbered ear tags to ensure 
that all participating research personnel were blinded to mouse genotype and treatment 
group. The number of mice utilized for each experiment was determined in pilot studies 
by identifying a sufficient group size that demonstrated statistical significance for 
accelerating rotarod activity. The minimal group size required for statistical power (0.85; 
alpha = 0.05) was n = 8, which also provided sufficient statistical power for histological 
assessments. PDE4 inhibitor and vehicle stocks were prepared and assigned generic 
labels, so that treatment identity was masked to the individual performing the oral 
gavages or s.c injections. The genotype and treatment status of individual animals 
remained unknown until data analysis was completed, whereupon groups were de-
identified. PDE4 inhibitor treatment was initiated in either 1 or 3 month-old mice by daily 
oral gavage, with treatment continuing for 6-9 months. The rationale for treating 1 
month-old mice is that this roughly approximates the age at which a genetic diagnosis of 
JNCL is usually made in children (i.e. 5-10 years), recognizing the caveats associated 
with human-rodent age equivalent estimates[225]. Delaying treatment until 3 months of 
age was performed to determine whether PDE4 inhibitors can impact advanced disease, 
since a positive diagnosis of CLN3 disease in children is often delayed. Body weights 
were recorded on a weekly basis after drug treatment commenced until completion of 
the study, since PDE4 inhibitors have been associated with weight loss[222]. 
8) Accelerating rotarod.  
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Motor activity of mice (n=5-8/group) was monitored with an AccuRotor 4-Channel 
Rotarod (Omnitech Electronics, Inc., Columbus, OH) using a 3 cm diameter rod [226]. 
Mice were subjected to testing over 4 consecutive days with a training period in the AM 
and testing period in the PM that were separated by 2 h. All trials were conducted during 
the same time of day for consistency. During the training period (one trial in the AM), 
mice were placed on the rotarod that was set to a constant speed of 4 rpm for 5 min. For 
the testing period, the apparatus was set to accelerate from 0 to 40 rpm over 5 min. The 
rotation speed of 40 rpm was maintained after the 5 min acceleration phase and the 
latency to fall was digitally recorded by the instrument. Each mouse was subjected to 
three afternoon trials daily with at least 20 min rest between each run. 
9) Blood chemistry analysis.  
To assess the safety profile of chronic PDE4 inhibitor dosing in juvenile mice, blood 
chemistry analysis was performed at 2-3 month intervals throughout the study. Blood 
was collected from the facial vein into heparinized capillary tubes and transferred to 
Vetscan® Comprehensive Diagnostic Panel rotors (Abaxis, Union City, CA), which 
measured alanine aminotransferase (ALT), albumin (ALB), alkaline phosphatase (ALP), 
amylase (AMY) total calcium (Ca2+), creatinine (CRE), globulin (GLOB), glucose (GLU), 
phosphorus (PHOS), potassium (K+), sodium (Na2+), total bilirubin (TBIL), total protein 
(TP), and urea nitrogen (BUN). 
10) Histology and quantitation of ocular inclusions.  
As another assessment of safety/toxicity of PDE4 inhibitors in juvenile mice, organs 
were collected following sacrifice for histopathological assessment by a board-certified 
pathologist with expertise in mouse toxicology studies (Samuel M. Cohen). The following 
tissues were fixed in 10% formalin and sent to AML Laboratories (Baltimore, MD) for 
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sectioning and H&E staining: kidney, stomach, liver, lung, spleen, heart, cervical lymph 
nodes, testes, thymus, trachea, muscle, spinal cord, larynx, pancreas, adrenal gland, 
aorta, bladder, colon, esophagus, small intestine, and femur/bone marrow. 
 To evaluate ocular inclusions, eyes were dissected under a microscope to remove 
the cornea and lens. Dissected eye cups were washed in PBS and embedded in 
acrylamide, whereupon cryostat sections (8 µm) were prepared to include the optic 
nerve. The most central optic nerve section was chosen for each eye, where a series of 
sequentially overlapping 10x images were taken covering the entire section using 
fluorescence microscopy (TRITC filter). Inclusions from each retinal layer were counted 
in a masked fashion using ImageJ software. 
11) cAMP quantitation.  
Various brain regions that are known to be affected in in Cln3Δex7/8 mice [i.e. 
somatosensory barrel field cortex (S1BF), visual cortex (VC), hippocampus (HPC), and 
thalamus (TH)] were dissected from vibratome sections of WT and Cln3Δex7/8 mice at 7 
and 12 months of age (n=5-10 per group), whereupon cAMP levels were quantified 
using a cAMP ELISA kit (Enzo, Farmingdale, NY). cAMP concentrations were 
normalized to the amount of total protein collected to account for differences in tissue 
size. In some experiments where only tissue sections were available, cAMP levels were 
assessed by immunofluorescence staining as described below. 
12) Immunofluorescence and confocal microscopy of PDE4 or vehicle treated 
mice.  
Coronal brain sections were prepared from vehicle or PDE4 inhibitor treated WT and 
Cln3Δex7/8 mice at the end of the 6 month dosing period as previously described with 
minor modifications[227]. Briefly, animals were deeply anesthetized using sodium 
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pentobarbital and transcardially perfused with saline followed by 4% paraformaldehyde 
(PFA). The brain was removed, post-fixed in 4% PFA overnight and cryoprotected with 
30% sucrose overnight prior to embedding in optimal cutting temperature medium. Free-
floating cryostat sections (30 µm) were incubated overnight at 4°C with antibodies 
specific for cAMP (1:200, Santa Cruz, Dallas, TX), GFAP (1:500, Dako, Carpinteria, CA), 
GLAST (1:200), LAMP-1 (1:250), or CD68 (1:200, all from Abcam, Cambridge, MA) 
followed by appropriate biotin-streptavidin conjugated secondary antibodies (Jackson 
Immunoresearch, West Grove, PA) and detection with either streptavidin-AlexaFluor 592 
or -AlexaFluor 488 (Invitrogen, Carlsbad, CA). TrueBlack (Biotium, Hayward, CA) was 
used to quench autofluorescent inclusions in Cln3Δex7/8 tissues. Immunofluorescence 
staining was visualized using a Carl Zeiss LSM 710 META confocal microscope with a 
40x oil immersion objective in a FOV 450×450 µm (200x magnification) or 225×225 µm 
FOV (400x magnification). Tile images were acquired to visualize the entire S1BF (810 
μm×1080 μm) or TH (810 μm×810 μm) of each section (two tissue slices per brain 
region per mouse). Tile images for GLAST quantitation were acquired at 270 μm×270 
μm for greater resolution. For image quantification, 200 μm×200 μm non-overlapping 
regions of interest (ROI) were positioned throughout the S1BF (total of 9 ROIs) and TH 
(total of 6 ROIs) using AxioVision software (Zeiss), whereupon total values from all 6-9 
ROIs were averaged for each of the two sections per mouse. Individual slice values per 
mouse were analyzed using SPSS to evaluate statistical significance using a mixed 
linear model approach. Results are reported as the mean intensity staining values 
(GFAP and GLAST) or area (CD68 and LAMP-1) determined by a custom software 
program incorporating the Visual Basic function of AxioVision (developed by Dr. Nikolay 
Karpuk, University of Nebraska Medical Center). To quantify cAMP expression levels in 
the brain, 6 non-overlapping 40x images in the TH, HPC, and VC from 5 mice per group 
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were acquired. Images were processed as described above and results are reported as 
the mean staining intensity values. 
13) AAV Vector Production and Purification.  
scAAV genomes were engineered to encode green fluorescent protein (GFP) or human 
CLN3 cDNA (NM_000086.2) under the control of the chicken-β-actin/cytomegalovirus 
hybrid promoter or the mouse minimal MeCP2 promoter [228]. Viral packaging was 
performed by SAB Technology (Philadelphia, PA). Briefly, viruses were packaged by 
standard triple transfection of helper, packaging (AAV2/9), and ITR-containing plasmids 
into HEK293 cells. Vectors were purified by cesium chloride gradient centrifugation and 
titers were determined by silver staining. 
14) In vivo administration of scAAV9 virus.  
One month-old male WT and CLN3ex7/8 mice (n=5-8/group) were randomized into 
vehicle or virus treatment groups and received a single i.v. injection of 2x1012 vg 
scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, scAAV9/MeCP2-GFP, or scAAV9/β-
actin-GFP or vehicle (PBS) via the retro-orbital sinus under isoflurane anesthesia. Body 
weights were recorded at weekly intervals throughout the study and blood chemistry 
analysis was conducted every 2 months post-injection. 
15) Immunofluorescence staining and confocal microscopy of scAAV9 treated 
mice.  
Representative coronal brain sections were prepared from CLN3Δex7/8 mice receiving i.v. 
injections of scAAV9 constructs as well as WT and CLN3Δex7/8 vehicle treated animals at 
5 months post-injection as previously described with minor modifications [159]. Briefly, 
animals were deeply anesthetized using sodium pentobarbital and transcardially 
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perfused with saline followed by 4% paraformaldehyde (PFA). The brain was removed, 
post-fixed in 4% PFA overnight and cryoprotected with 30% sucrose overnight prior to 
embedding in optimal cutting temperature (OCT) medium. Free-floating cryostat sections 
(30 µm; two tissue slices per brain region per mouse) were prepared and slices 
containing the desired brain regions (S1BF and TH) were permeabilized by incubation in 
0.1 M PBS containing 0.3% Triton-X (2X, 5 min each). Tissues were then blocked with 
10% donkey serum for 1 h at room temperature and incubated overnight at 4°C with 
primary antibodies, including a polyclonal rabbit anti-mitochondrial ATP synthase subunit 
C (kindly provided by Dr. Susan Cotman, Harvard Medical School, Boston, MA), Iba-1 
(1:200, BioCare Medical, Concord, CA), NeuN (1:500, Abcam, San Francisco, CA), 
CD68 (1:200, Abcam), LAMP-1 (1:250, Abcam), or GFP (1:500, Abcam, incubated with 
tissues for 72 h). After 3 washes with 1X PBS, brain sections were incubated with an 
appropriate biotin-streptavidin conjugated secondary antibody and DAPI for nuclear 
identification. Autofluorescent inclusions in CLN3Δex7/8 tissues were quenched with a 
70% solution of Sudan Black for 10 min [159] or TrueBlack according to the 
manufacturer’s recommendations (Biotium, Hayward, CA). Immunofluorescence was 
visualized using a Carl Zeiss LSM 710 META confocal microscope with a 40X oil 
immersion objective in a FOV 450×450 µm (200× magnification) or 225×225 µm FOV 
(400× magnification). Tile images were acquired to visualize the entire S1BF (810 
μm×1080 μm) or TH (810 μm×810 μm) for each section. For image quantification, 200 
μm×200 μm non-overlapping regions of interest (ROI) were positioned throughout the 
S1BF (total of 9 ROIs) and TH (total of 6 ROIs) using AxioVision software (Zeiss), 
whereupon total values from all 6-9 ROIs were averaged for each slice. Individual slice 
averages per mouse were analyzed using SPSS to evaluate statistical significance using 
a mixed linear model approach. Results are reported as the mean intensity staining 
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values (GFAP), area (CD68 and LAMP-1), or region of interest count (SCMAS) as 
determined using AxioVision software [159]. 
 To quantify transgene expression in various CNS cell types, co-localization of 
transgene-positive cells (GFP+) with NeuN+ neurons and GFAP+ astrocytes was 
determined using the Imaris program (Bitplane; Zurich, Germany). The Imaris auto-
threshold co-localization function was used to determine non-random signal co-
localization in the red and green channels [229]. Next, settings were determined on a 
per image basis and quantitative spot analysis [230] was performed to determine the 
number of GFP+, GFAP+, and NeuN+ cells. Results are reported as the percentage of 
GFP+NeuN+ cells or GFP+GFAP+ cells. 
16) Western Blot.  
Coronal sections (1,200 µm thick) were prepared from acute brain slices using a 
vibratome while bathed in ice-cold ACSF, whereupon the S1BF, STR, VC, TH, CB, and 
HPC were dissected to collect total protein extracts. Tissues were homogenized in cell 
lysis buffer [50 mM Tris-HCl, pH 7.5; 150 mM sodium chloride; 0.5% Triton X-100; 1 mM 
sodium orthovanadate; 10 mM sodium fluoride; 0.5 mM phenylmethanesulfonyl fluoride 
and supplemented with complete protease inhibitor (Roche, South San Francisco, CA) 
and phosphatase inhibitor (Thermo Scientific, Waltham, MA) tablets]. Twenty µg of total 
protein was run on 10% PAGE gels, whereupon Western blotting was performed as 
previously described [159]. Blots were probed with anti-GFP (1:500, Abcam) and 
developed using chemiluminescence. Blots were stripped and re-probed with an 
antibody against β-actin (Sigma, St. Louis, MO) to confirm uniformity in gel loading. Blots 
were quantitated by densitometry analysis using an Alpha Innotech imager (Protein 
Simple, San Jose, CA) with signals normalized to β-actin. 
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17) Real-time quantitative PCR.  
Mice were perfused with PBS and brain regions dissected from vibratome sections as 
described above. RNA was isolated using the Trizol reagent and treated with DNase I 
(Invitrogen, Carlsbad, CA) prior to cDNA conversion using an iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA). cDNA was used for real-time PCR with Applied Biosystems 
Gene Expression Master Mix and an Assays on Demand primer/probe set specific for 
exons 7-8 of human CLN3 (Hs01029238) and the housekeeping gene GAPDH. Relative 
expression of AAV9/β-actin-hCLN3 was then calculated for each region relative to 
AAV9/MeCP2-hCLN3 after GAPDH normalization. 
18) Statistics.  
For Seahorse mitochondrial and glycolysis assays, results were evaluated using an 
analysis of variance [231] [231] and multiple group Tukey-Krammer post-hoc to compare 
between groups. A Student’s t-test was used to analyze mitochondrial number. 
Quantification of Ca2+ oscillations was assessed using a mixed linear model, where 
variables included, group, genotype, coverslip, and number of oscillations per cell. 
Statistical significance between groups was analyzed in SPSS (IBM SPSS Statistic, 
Armonk).  All assays for therapeutic studies were blinded throughout the entirety of data 
collection and analysis. For body weight comparisons, weights were averaged for mice 
in each treatment group and were analyzed by repeated measures ANOVA followed by 
a post-hoc Tukey test. Quantification of CD68, GFAP, LAMP-1, and GLAST 
immunofluorescence staining was assessed using a mixed linear model, where the 
variables included group, animal, slice, and staining area or intensity. Statistical 
significance between groups for each brain region was analyzed in SPSS (IBM SPSS 
Statistic, Armonk). For accelerating rotarod analysis were analyzed by a mixed linear 
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model in SPSS. Quantification of cAMP was assessed by one-way ANOVA in GraphPad 
Prism (La Jolla, CA). 
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Chapter 3: Astrocytes in Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) display 
metabolic and calcium signaling abnormalities 
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Abstract 
 Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) is a lysosomal storage disease 
caused by autosomal recessive mutations in CLN3. Children with JNCL experience 
progressive visual, cognitive, and motor deterioration with a decreased life expectancy 
(late teens-early 20s). Neuronal loss is thought to occur, in part, via glutamate 
excitotoxicity; however, little is known about astrocyte glutamate regulation in JNCL. 
Spontaneous Ca2+ waves were reduced in murine Cln3Δex7/8 astrocytes, which was also 
observed following glutamate or cytokine exposure. Astrocyte glutamate transport is an 
energy-demanding process and disruptions in metabolic pathways could influence 
glutamate homeostasis in Cln3Δex7/8 astrocytes. Indeed, basal mitochondrial respiration 
and ATP production were significantly reduced in Cln3Δex7/8 astrocytes. These changes 
were not attributable to reduced mitochondria, since Cln3Δex7/8 astrocytes displayed 
significant increases in mitochondrial numbers. Interestingly, despite these functional 
deficits in Cln3Δex7/8 astrocytes, glutamate transporter expression and glutamate uptake 
were not dramatically affected. Concurrent with impaired astrocyte metabolism and Ca2+ 
signaling, murine Cln3Δex7/8 neurons were hyper-responsive to glutamate, as reflected by 
heightened and prolonged Ca2+ signals. These findings identify intrinsic metabolic and 
Ca2+ signaling defects in Cln3Δex7/8 astrocytes that may contribute to neuronal 
dysfunction in CLN3 disease. 
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Introduction 
 Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), or CLN3 disease, is a pediatric 
lysosomal storage disorder afflicting an estimated 1 in every 100,000 live births [60-62]. 
Children appear healthy until the onset of disease symptoms between the ages of 5-10 
that initiates as vision loss, followed by seizures, dementia, and motor and cognitive 
decline, with premature death by the late teens to-early 20s [60, 74, 232]. JNCL is 
caused by autosomal recessive mutations in CLN3 [60, 233]. Most common is a 1.02kb 
deletion that occurs in approximately 85% of mutated CLN3 alleles, which is thought to 
encode a truncated protein that is minimally expressed and/or rapidly degraded [60] 
[234]. While its function still remains unknown, CLN3 has been implicated in multiple 
cellular processes, including lysosomal acidification, amino acid transport, mitochondrial 
function, and intracellular Ca2+ regulation [86, 89-92]. 
 CLN3 pathology is characterized by the accumulation of lysosomal inclusions in all 
cell types, with neurons most dramatically affected [71, 72]. Current evidence suggests 
that inclusions are not a direct cause of neuron death, since many inclusion-positive 
neurons are not lost during the disease [88, 100]. In terms of alternative possibilities, 
previous studies have reported a disruption in glial function and potential loss of neuron 
homeostatic support that might contribute to neuron dysfunction in JNCL. In particular, 
astrocytes have increased hemichannel (HC) opening during early disease that can 
serve as a conduit for ATP, Ca2+, and glutamate release [159, 235]. In addition, 
Cln3Δex7/8 microglia exist in a primed pro-inflammatory state, producing exaggerated 
levels of several cytokines, such as IL-1β and TNF-α, than can potentiate astrocyte HC 
opening and augment glutamate release, disrupting cellular homeostasis [123, 160]. 
These data are supported by the finding that glutamate levels are elevated in the brains 
of both JNCL patients as well as CLN3 mouse models [104, 236-238]. However, the 
underlying mechanisms responsible for elevated glutamate in the JNCL brain remain to 
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be identified, but collectively the available evidence suggests a disruption in vital 
astrocyte homeostatic functions is a contributing factor.  
 Astrocytes are the primary cell type responsible for regulating extracellular 
glutamate levels to maintain neuronal homeostasis [138]. Astrocyte projections surround 
the tripartite synapse and remove glutamate primarily through the Na2+-dependent 
glutamate symporters GLAST and GLT-1 [139]. Glutamate transporter action is an 
energy-demanding process, which requires the Na+/K+ ATPase to produce large 
quantities of ATP [239]. Disruption in any step of the glutamate uptake pathway can 
result in increased synaptic glutamate concentrations that are capable of inducing 
neuron excitotoxicity [240, 241]. In addition to CLN3 disease, alterations in glutamate 
homeostasis have been reported in several neurodegenerative disorders, including 
Alzheimer’s disease, Parkinson’s disease, and other lysosomal storage disorders, such 
as Niemann-Pick type C [146-148, 242]. Besides maintaining CNS metabolic 
homeostasis, astrocytes control neurotransmitter release and neuronal signaling, in part, 
by regulating Ca2+ levels at the synapse [243-245]. Astrocytes interpret neuronal 
signaling patterns and communicate to surrounding cells via Ca2+ waves, which act as a 
glial signaling system for the propagation of both paracrine and distant signals in the 
CNS [246, 247]. Strong evidence has emerged suggesting that perturbations in 
astrocyte signaling Ca2+ contribute to neuronal hyperactivity, loss of astrocyte 
homeostatic support, and disruption of the extracellular milieu [248, 249].  
 Here we present evidence of intrinsic abnormalities in Cln3Δex7/8 astrocytes that may 
account for, in part, neuroexcitotoxicity in the CLN3 brain. Specifically, Cln3Δex7/8 
astrocytes displayed reduced Ca2+ waves, impaired mitochondrial activity, and ATP 
production. However, despite these intrinsic defects, glutamate transporter expression 
and glutamate uptake were not significantly different between Cln3Δex7/8 and WT 
astrocytes. Cln3Δex7/8 neurons were hyper-responsive to glutamate, exhibiting elevated 
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and prolonged Ca2+ signals. Collectively, these findings reveal mechanisms that could 
impair astrocyte-neuron glutamate crosstalk and contribute to neuronal excitotoxicity 
during CLN3 disease progression. 
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Results 
CLN3 mutation causes perturbations in astrocyte Ca2+ oscillations. Astrocytes 
utilize Ca2+ signaling to communicate with surrounding cells as well as regulate synaptic 
firing. Glutamate released from neurons activates astrocyte glutamate transporters and 
triggers an increase in astrocytic intracellular Ca+2 [250, 251]. Elevated intracellular Ca2+ 
in astrocytes can activate multiple glutamate regulatory pathways, including trafficking of 
GLAST transporters to the membrane, mobilizing mitochondria to increase energy 
production, and increased Na+-Ca2+ exchange pump activity to reduce K+ levels and 
neuronal firing [246, 252-254]. Unchecked neuronal activity from impaired astrocyte 
regulation can increase glutamate concentrations, further potentiating glutamate 
dysregulation. To determine whether Ca2+ transients are perturbed in Cln3Δex7/8 
astrocytes, live-cell Ca2+ imaging was performed. Cln3Δex7/8 astrocytes displayed 
decreased spontaneous Ca2+ oscillations under resting conditions, which was also 
observed when cells were exposed to proinflammatory cytokines that have previously 
been shown to be over-produced by Cln3Δex7/8 microglia (Figure 1) [123]. Following the 
assessment of basal spontaneous Ca2+ activity, astrocytes were exposed to 10mM 
glutamate to model extracellular neuronal signaling. Glutamate treatment increased 
intracellular Ca2+ in both WT and Cln3Δex7/8 astrocytes compared to baseline; however, 
levels were still significantly reduced in Cln3Δex7/8 cells (Figure 1). A single astrocyte is 
capable of simultaneously regulating multiple synapses, while at the same time one 
neuron may have its synapses enveloped by multiple astrocytes. Therefore, the 
reduction in Cln3Δex7/8 astrocyte Ca2+ signaling may not only have intrinsic effects or 
regulate local neuronal activity, but could also disrupt larger signaling networks. 
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Figure.  3.1 
 
 
 
 
 
 
 
CLN3 mutation alters astrocyte Ca+ responses. Primary WT and Cln3∆ex7/8 astrocytes 
were unstimulated or treated with TNF-α and IL-1β (10ng/mL each) for 24 h and loaded 
with the Ca2+ indicator dye Fluo4-AM. Following a 5 min period for baseline readings, 
cells were exposed to 10mM glutamate (Glu) and the amplitude of the first Ca2+ 
response was calculated (*, p < 0.05; **, p < 0.01; ****, p < 0.0001).  
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Mitochondrial respiration is impaired in Cln3Δex7/8 astrocytes. During periods of 
robust neuronal activity, astrocyte energy demands increase to maintain homeostatic 
functions [239]. Although neurons possess the highest metabolic requirements in the 
CNS, astrocytes account for approximately 20% of the energy usage in the brain during 
consciousness [255]. Astrocytes must maintain mitochondrial and glycolytic function to 
regulate neurotransmitter and ion homeostasis and synaptic activity. Previous studies 
support mitochondrial dysfunction in JNCL, including increased mitochondrial oxidative 
stress molecules, mitochondrial membrane depolarization, and alterations in 
mitochondrial morphology [89, 91, 256-258]. However, most of these studies were 
conducted with an immortalized Cln3Δex7/8 cerebellar cell line and none have examined 
mitochondrial activity in real-time in astrocytes. Here we utilized Seahorse bioassays to 
determine whether Cln3Δex7/8 astrocytes display defects in mitochondrial respiration. 
Under resting conditions, both basal respiration and ATP production were significantly 
reduced in Cln3Δex7/8 astrocytes (Figure 2). Mitochondrial defects in Cln3Δex7/8 astrocytes 
were also evident when cells were exposed to JNCL danger signals (ceramide + 
neuronal lysate) or proinflammatory cytokines (TNF-α + IL-1β; Figure 2). These 
mitochondrial defects could be attributed, in part, to dampened intracellular Ca2+ in 
Cln3Δex7/8 astrocytes, since mitochondrial respiration and ATP production are Ca2+-
dependent and the failure to raise intracellular Ca2+ in Cln3Δex7/8 cells would be expected 
to interfere with mitochondrial function. Importantly, total protein concentrations were 
equivalent between WT and Cln3Δex7/8 astrocytes pre/post assay, indicating lack of 
toxicity. 
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial respiration is impaired in Cln3Δex7/8 astrocytes. Primary WT and 
Cln3∆ex7/8 astrocytes were unstimulated or treated with TNF-α and IL-1β (10ng/mL each) 
or C6 ceramide (5μM) and neuronal lysate (NL) for 24 h, whereupon OX PHOS activity 
was examined using Seahorse Bioscience assays. (A) Basal mitochondrial respiration 
and (B) ATP production was measured based on oxygen consumption rate (OCR). 
Significant differences in mitochondrial function between WT and CLN3Δex7/8 astrocytes 
are denoted by asterisks (*, p < 0.05; **, p < 0.01). 
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 To determine whether defective mitochondrial activity in Cln3Δex7/8 astrocytes was 
due to alterations in mitochondrial number, cells were stained with the mitochondrial-
selective dye MitoTracker Red CMXRos. Cln3Δex7/8 astrocytes displayed significantly 
more mitochondria per cell compared to WT (Figure 3), indicating that impaired 
mitochondrial respiration in Cln3Δex7/8 astrocytes is not due to reduced mitochondrial 
biomass, but more likely senescent mitochondria due to mitophagy defects, which has 
been found to occur in JNCL models [89, 259, 260]. Without sufficient ATP generation in 
the face of high neuronal activity, Cln3Δex7/8 astrocytes may become overwhelmed and 
unable to regulate the CNS extracellular milieu. 
 In instances of increased neuronal activity or distress, astrocytes augment 
glycolysis to produce more ATP. Since mitochondrial metabolism and ATP production 
were reduced in Cln3Δex7/8 astrocytes, we next examined whether cells shift to a more 
glycolytic profile to compensate. No significant differences in glycolytic rates were 
observed between Cln3Δex7/8 and WT astrocytes (Figure 4). This indicates that Cln3Δex7/8 
astrocytes do not compensate for the reduction in mitochondrial ATP production by 
augmenting glycolytic pathways. 
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Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cln3Δex7/8 astrocytes display increased mitochondrial abundance. Primary WT and 
Cln3∆ex7/8 astrocytes were stained with MitoTracker Red CMX ROS to quantify 
mitochondria. Mitochondrial numbers were calculated using a spot analysis program with 
Imaris Scientific 3D/4D Image Processing & Analysis Software (**, p < 0.01). 
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Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLN3 mutation does not affect astrocyte glycolytic activity. Primary WT and 
Cln3∆ex7/8 astrocytes were unstimulated or treated with TNF-α and IL-1β (10ng/mL each) 
or C6 ceramide (5μM) and neuronal lysate (NL) for 24 h, whereupon glycolytic activity 
was examined using Seahorse Bioscience assays. (A) Fmitsis, (B) Maximum capacity, 
and (C) Glycolytic reserve was measured based on extracellular acidification rate 
(ECAR). 
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Glutamate transporter expression and uptake are not significantly altered in 
Cln3Δex7/8 astrocytes. The excitatory neurotransmitter glutamate is tightly regulated in 
the CNS and the pathways responsible for maintaining glutamate homeostasis are 
highly conserved [261, 262]. Disruptions in glutamate regulation have been implicated in 
CLN3 disease, where glutamate levels are elevated in CLN3 mouse models and 
treatment with NMDA or AMPA receptor antagonists improved motor function [104, 146, 
236, 237, 242, 263]. To explore the possibility of intrinsic alterations in glutamate 
transport in Cln3Δex7/8 astrocytes, we first examined glutamate transporter expression by 
Western blot.  No significant differences in either GLT-1 or GLAST expression were 
detected between WT and Cln3Δex7/8 astrocytes under resting conditions or following 
cytokine (TNF-α + IL-1β) or glutamate treatment (data not shown). To determine whether 
glutamate uptake was affected in Cln3Δex7/8 astrocytes, cells were assessed for their 
ability to remove excess glutamate from the extracellular milieu using an Amplex Red 
glutamic acid assay. Following a 24 h treatment with danger signals (ceramide + 
neuronal lysate) or cytokines (TNF-α + IL-1β), astrocytes were exposed to a bolus of 
glutamic acid (1mM), whereupon the amount of glutamate remaining in the supernatant 
at 30 min and 2 h was measured. Extracellular glutamate levels were similar between 
Cln3Δex7/8 and WT astrocytes in all treatment conditions (Figure 5). Collectively, the 
decreases in Ca2+ signaling and ATP production in Cln3Δex7/8 astrocytes do not 
significantly impact intrinsic glutamate regulatory pathways, instead suggesting possible 
defects in cell-cell communication with neurons. 
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Figure 3.5 
 
 
 
 
 
 
 
Glutamate uptake is not altered in Cln3Δex7/8 astrocytes. Primary WT and Cln3∆ex7/8 
astrocytes were treated with TNF-α and IL-1β (10ng/mL each) or C6 ceramide (5μM) 
and neuronal lysate (NL) for 24 h. Cells were then exposed to 1mM glutamate, 
whereupon supernatants were collected 30 min and 2 h later to evaluate residual 
extracellular glutamate concentrations. Results were normalized to the 1mM glutamate 
control.  
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Cln3Δex7/8 neurons are hyperexcitable to extracellular glutamate. Neurons are the 
principle cell type lost in CLN3 disease and this is thought to result, in part, from 
glutamate excitotoxicity [33, 71, 72, 104, 166]. Hyper-excitable or uninhibited excitatory 
neurons are a primary cause of seizures, which is a hallmark of disease in CLN3 
patients [264]. To investigate the sensitivity of Cln3Δex7/8 neurons to physiological 
glutamate concentrations at the synaptic cleft (i.e. ~25nM), live-cell Ca2+ imaging was 
performed [265-267]. Glutamate application evoked a significant increase in intracellular 
Ca2+ in Cln3Δex7/8 neurons, reflecting their hyper-sensitivity to glutamate (Figure 6). After 
a 1 min stimulation period, glutamate washout was performed, which returned 
intracellular Ca2+ levels to baseline in WT but not Cln3Δex7/8 neurons, which is often used 
as an indication of impending excitotoxicity [268-270]. Collectively, these studies suggest 
the existence of autonomous and non-cell autonomous mechanisms that may lead to 
glutamate dysregulation in CLN3 disease via impaired neuron and astrocyte activity. By 
extension, since Cln3Δex7/8 neurons are hyper-responsive to glutamate this could 
perpetuate glutamate release, which would ultimately lead to excitotoxicity and neuron 
death that is reminiscent of CLN3 disease.  
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Figure 3.6 
 
 
 
 
 
 
 
 
 
 
Ca2+ signaling is disrupted in Cln3∆ex7/8 neurons. Primary WT and Cln3∆ex7/8 neurons 
were loaded with Fluor4-AM. Following a 5 min period for baseline recordings, neurons 
were treated with 25nM L-glutamic acid and evaluated for a 420 sec period. 
Measurements were obtained using AxioVision software and are reported as the mean 
fluorescent intensity normalized to baseline values (*, p < 0.05). The arrow depicts the 
point of L-glutamic acid addition. 
  
61 
 
Discussion  
 Although CLN3 mutations were identified as the cause of JNCL in 1995, the precise 
function of CLN3 remains unknown [60, 86]. To date, CLN3 has been implicated in 
multiple processes critical for maintaining cellular homeostasis as well as dampening 
microglial proinflammatory activity [86, 89-92, 123]. Earlier studies have focused on the 
accumulation of lysosomal storage material within neurons, a hallmark of disease 
pathology and progression [60, 71, 72]. However, there is little evidence directly 
implicating lysosomal inclusions as the cause of neuronal death [54, 67]. For this reason, 
we chose to investigate other pathways that could contribute to neurodegeneration that 
is a hallmark of CLN3 disease. 
 One such pathway is glutamate regulation, which has been implicated as one mode 
of neurotoxicity in JNCL. However little is known about the mechanisms contributing to 
aberrant glutamate regulation in JNCL or the role of astrocytes in this process. It is likely 
that astrocyte activity influences neuronal survival in JNCL based on previous studies 
reporting that activated astrocytes coincide with brain regions where neurons are 
eventually lost in CLN3 mouse models [32, 33]. Likewise, it has been shown that 
increased astrocyte hemichannel activity and reduced expression of the glutamate 
transporter GLAST and glutamine synthetase are apparent in the Cln3Δex7/8 brain, which 
supports the concept of disrupted astrocyte glutamate regulation and homeostatic 
functions in JNCL [159]. Here we present a potential mechanistic model to account for 
increased extracellular glutamate in the JNCL brain, primarily centered on astrocyte-
neuron crosstalk because intrinsic astrocyte glutamate pathways are not dramatically 
affected (Figure 7).  
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Figure 3. 7  
 
 
 
 
 
 
 
 
 
 
 
 
Proposed mechanism for aberrant astrocyte-neuron crosstalk during CLN3 
disease. Glutamate uptake by astrocytes is an energy-demanding process and ATP 
production was significantly decreased in Cln3Δex7/8 astrocytes, which coincided with 
impaired Ca2+ signaling. Cln3Δex7/8 neurons were hyper-sensitive to physiological 
concentrations of glutamate, which elicited heightened and prolonged Ca2+ signals that 
with time may contribute to neuronal dysfunction and/or death. Gln, glutamine; Glu, 
glutamate; GLAST, glutamate-aspartate transporter; GLT-1, glutamate transporter 1. 
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 An interesting attribute of CLN3 disease that distinguishes it from other forms of 
Batten is the protracted nature of disease progression (occurs over a period of 10-15 
years) and the fact that disease symptoms do not typically manifest until around 5-10 
years of age [164, 271]. This suggests the existence of compensatory mechanisms to 
maintain CNS homeostasis until a disease threshold is achieved. Although the 
mechanisms responsible for this prolonged disease course are unknown, one possibility 
may be progressive glutamate accumulation that initially leads to excessive neuronal 
activity and ultimately cell death. This is also an attractive possibility from a clinical 
perspective, since seizures are often an early hallmark of CLN3 disease, which may be 
attributed to glutamate hyperactivity, followed by neuronal death that could be due to 
glutamate excitotoxicity [239, 272, 273]. We found that Cln3Δex7/8 neurons were hyper-
reactive in response to physiological glutamate concentrations at the synaptic cleft [268-
270]. By extension, not only do Cln3Δex7/8 neurons require less glutamate to be activated, 
but increased activation would augment glutamate release, perpetuating the pathological 
circuit. Cln3Δex7/8 neurons also maintained higher levels of intracellular Ca2+ following 
glutamate exposure, indicative of a longer activation state [274]. In addition, whereas 
intracellular Ca2+ levels in WT neurons returned to baseline within 1 min of stimulation, 
Cln3Δex7/8 neurons maintained exaggerated intracellular Ca2+ levels, which has been 
shown to precede excitotoxicity [248, 249]. It was recently reported that neuronal activity 
was exaggerated in the Cln3Δex7/8 hippocampus and cortex using electrophysiological 
recordings of acute brain slices, supporting the heightened neuronal responses 
presented here [158]. 
 Glutamate regulation is critical for maintaining optimal neuron-astrocyte signaling 
networks [137, 244]. This is an extremely energy-demanding process, requiring a 
constant supply of ATP that becomes even more pronounced during times of heightened 
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neuronal activity [239], as suggested by our findings of hyper-reactive Cln3Δex7/8 neurons. 
Previous reports have described several mitochondrial abnormalities in CLN3 cells, 
including morphological changes, increased oxidative stress molecules, and elevated 
membrane potentials [89, 91, 256-258]. However, most of these studies have been 
performed using immortalized cell lines and none have assessed mitochondrial function 
in astrocytes. Using Seahorse metabolic assays, mitochondrial basal respiration and 
ATP production were significantly lower in Cln3Δex7/8 astrocytes, even at the resting state. 
Mitochondrial function was also impaired when Cln3Δex7/8 astrocytes were exposed to 
JNCL-relevant stimuli. Importantly, these changes were independent of mitochondrial 
numbers, since Cln3Δex7/8 astrocytes harbored significantly more mitochondria on a per 
cell basis. This likely results from disruptions in autophagy and lysosomal degradation 
mechanisms that have been described in CLN3 disease [89, 231]. This is the first report 
to demonstrate disruptions in astrocyte mitochondrial function in the context of CLN3 
mutation.  
 Astrocytes utilize Ca2+ signaling to communicate with surrounding astrocytes and 
neurons, sense extracellular cues, and regulate synaptic activity [243-245, 275]. Here 
we show that Cln3Δex7/8 astrocytes have lower spontaneous Ca2+ oscillations under 
resting conditions and following exposure to danger signals/proinflammatory cytokines. 
Ca2+ transients were also significantly reduced in Cln3Δex7/8 astrocytes in response to 
extracellular glutamate. By extension, if Cln3Δex7/8 astrocytes are less responsive to 
extracellular signals and are unable to properly regulate synaptic activity, Cln3Δex7/8 
neurons will continue to fire and release more glutamate, resulting in the pathological 
propagation of a dysfunctional glutamate circuit in CLN3 disease.  
 In summary, our study supports the following model to account for neuronal 
hyper-excitability in the context of CLN3 mutation (Figure 7). First, CLN3 loss leads to 
cell autonomous changes in neurons, resulting in hyper-sensitivity to low glutamate 
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concentrations. Excessive excitatory activity in Cln3Δex7/8 neurons triggers heightened 
glutamate release into the synaptic cleft and the surrounding extracellular milieu. 
Persistent elevations in extracellular glutamate are known to further induce pre-existing 
neuroinflammatory pathways that trigger the release of cytotoxic mediators, inhibit 
cellular homeostatic functions, and induce apoptosis [276-278]. Mitochondrial basal 
respiration, ATP production, and spontaneous Ca2+ oscillations were significantly 
reduced in Cln3Δex7/8 astrocytes, which can have a major impact on cell signaling and 
synaptic activity. Without proper astrocytic regulation, synaptic firing can escalate in 
Cln3Δex7/8 neurons, which augments glutamate release and perpetuates the pathological 
cycle. Ultimately, this could be one mechanism to account for eventual neuronal loss 
associated with CLN3 disease. 
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Chapter 4: Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease 
(CLN3) 
Published in Annals of Neurology 80(6):909-923, 2016 
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ABSTRACT 
 Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), or juvenile Batten disease, is a 
pediatric lysosomal storage disease caused by autosomal recessive mutations in CLN3, 
typified by blindness, seizures, progressive cognitive and motor decline, and premature 
death. Currently, there is no treatment for JNCL that slows disease progression, which 
highlights the need to explore novel strategies to extend the survival and quality-of-life of 
afflicted children. Cyclic AMP (cAMP) is a second messenger with pleiotropic effects, 
including regulating neuroinflammation and neuronal survival. Here we investigated 
whether three phosphodiesterase-4 (PDE4) inhibitors (rolipram, roflumilast, and PF-
06266047) could mitigate behavioral deficits and cell-specific pathology in the Cln3Δex7/8 
mouse model of JNCL. In a randomized, blinded study, wild type (WT) and Cln3Δex7/8 
mice received PDE4 inhibitors daily beginning at 1 or 3 months of age and continuing for 
6-9 months, with motor deficits assessed by accelerating rotarod testing. The effect of 
PDE4 inhibitors on cAMP levels, astrocyte and microglial activation (GFAP and CD68, 
respectively), lysosomal pathology (LAMP-1), and astrocyte glutamate transporter 
expression (GLAST) were also examined in WT and Cln3Δex7/8 animals. cAMP levels 
were significantly reduced in the Cln3Δex7/8 brain, which were restored by PF-06266047. 
PDE4 inhibitors significantly improved motor function in Cln3Δex7/8 mice, attenuated glial 
activation and lysosomal pathology, and restored glutamate transporter expression to 
levels observed in WT animals with no evidence of toxicity as revealed by blood 
chemistry analysis. These studies reveal neuroprotective effects for PDE4 inhibitors in 
Cln3Δex7/8 mice and support their therapeutic potential in JNCL patients. 
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INTRODUCTION 
 Juvenile Neuronal Ceroid Lipofuscinosis (JNCL or CLN3 disease) is an autosomal 
recessive lysosomal storage disease resulting from CLN3 mutations, with an estimated 
incidence of 1 in 100,000 live births [60, 233]. Children with JNCL appear healthy at 
birth, with progressive vision loss typically being the first sign of disease that presents 
around 4-7 years of age. Later, affected children develop motor dysfunction that 
manifests as Parkinson-like symptoms, along with seizures and cognitive deterioration, 
with a life expectancy of late teens to 20s [62]. MRI findings include cortical and 
cerebellar atrophy with abnormally high signal intensity in the white matter, reflecting 
moderate demyelination [279, 280]. The protracted nature of the disease coupled with 
the current lack of effective therapeutics, highlights the need to identify novel 
approaches to improve the longevity and quality-of-life for these patients. 
 In JNCL mouse models, reactive glia are apparent within 1-3 months of age and 
coincide with areas of eventual neuron loss, which is significantly delayed in comparison 
(i.e. 12-18 months) [33, 227]. Current evidence supports non-cell autonomous influences 
of diseased glia in JNCL pathogenesis in addition to intrinsic neuronal deficits. For 
example, Cln3Δex7/8 microglia are primed to produce exaggerated levels of several 
inflammatory mediators in response to danger signals encountered in the JNCL brain 
[123]. Likewise, molecules critical for astrocyte glutamate regulation are dramatically 
reduced in Cln3Δex7/8 mice, including GLAST and glutamine synthetase [227]. These 
findings support the neurotransmitter imbalance described in CLN3 mouse models, 
namely excessive glutamate and reduced GABA, which has been implicated in 
neurotoxicity [104, 236, 281]. 
 Cyclic AMP (cAMP) is a second messenger that can regulate a variety of signaling 
events involved in learning and memory and synaptic plasticity [182, 183]. Reductions in 
cAMP can have broad effects, ranging from a generalized negative impact on neuronal 
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homeostasis, promotion of microglial proinflammatory activity, and reduced glutamate 
transporter expression in astrocytes [282-284]. cAMP levels are regulated by a balance 
between synthesis and degradation, mediated by adenylyl cyclase and 
phosphodiesterases (PDEs), respectively. There are a total of 11 PDE enzyme families, 
with PDE4 most prominently expressed in the CNS [285]. PDE4 inhibitors have shown 
beneficial effects in a wide range of neurodegenerative disorders, by limiting neuronal 
apoptosis and neuroinflammation as well as augmenting glutamate transporter 
expression [185, 186, 282, 286]. Based on our previous findings demonstrating 
reductions in GLAST expression in Cln3Δex7/8 astrocytes [227], exaggerated 
proinflammatory mediator production in Cln3Δex7/8 microglia [123], and intrinsic neuron 
pathology as shown by other groups [33, 91], we surmised that PDE4 inhibitors would 
represent an excellent means to target this triad of cellular dysfunction. 
 Here we show that cAMP levels are significantly reduced in several brain regions 
of Cln3Δex7/8 mice where neuropathology occurs. Treatment of Cln3Δex7/8 animals with 
three distinct PDE4 inhibitors (rolipram, roflumilast, or PF-06266047) significantly 
improved motor function over a 6 month period. PDE4 inhibitors also reduced glial 
activation and lysosomal pathology as well as restored impaired glutamate transporter 
expression in Cln3Δex7/8 mice to WT levels. Importantly, the beneficial effects of PDE4 
inhibitors were still observed when treatment was delayed until 3 months of age, 
suggesting that they are capable of improving more advanced disease. This is the first 
study demonstrating that PDE4 inhibitors are effective at reducing motor deficits and 
pathological attributes of JNCL, supporting their potential therapeutic utility. 
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RESULTS 
Brain cAMP levels are significantly reduced in Cln3Δex7/8 mice. Reductions in cAMP-
mediated signaling have been shown to impact neurobehavioral and cognitive function in 
normal aging, as well as in neurodegenerative diseases [182, 183]. In addition, 
decreased cAMP levels are associated with proinflammatory responses and reductions 
in glutamate transporter expression [282, 283], which agrees with our prior findings of 
increased inflammatory mediator production by Cln3Δex7/8 microglia and decreased 
GLAST expression in the Cln3Δex7/8 brain[123, 227]. To determine whether these 
changes may be linked to alterations in cAMP, cAMP levels were quantitated by ELISA 
in brain regions where neuropathology occurs in Cln3Δex7/8 mice [33]. cAMP was 
significantly reduced in the thalamus (TH) of Cln3Δex7/8 mice at 7 months, whereas the 
hippocampus (HPC) and visual cortex (VC) showed a similar trend but did not reach 
statistical significance (Fig 1, upper panel). At 12 months, significant reductions in cAMP 
were observed in the TH, HPC, and VC of Cln3Δex7/8 mice compared to WT animals (Fig 
1, lower panel). Immunofluorescence staining for cAMP confirmed the reductions in 7 
month-old mice (data not shown). cAMP levels were similar in the somatosensory barrel 
field cortex (S1BF) of WT and Cln3Δex7/8 mice at both ages examined (Fig 1), 
emphasizing the region-specific neuropathology that is observed in JNCL. 
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cAMP levels are decreased in vulnerable brain regions of Cln3Δex7/8 mice. Cln3Δex7/8 
and WT mice (n=5-10/group) were sacrificed at 7 (top panel) or 12 months of age 
(bottom panel), whereupon cAMP levels were quantified in the thalamus (TH), 
hippocampus (HPC), visual cortex (VC), and somatosensory barrel field cortex (S1BF) 
by ELISA and normalized to total protein to account for differences in tissue size. 
Results are combined from 2 independent experiments and significant differences 
between WT and Cln3Δex7/8 mice are denoted by asterisks (*, p < 0.05). 
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PDE4 inhibitors reverse motor deficits in Cln3Δex7/8 mice. As previously mentioned, 
PDE4 inhibitors improve cognitive and motor function in various acute and chronic 
neurodegenerative diseases, including traumatic brain injury, spinal cord injury, 
Alzheimer disease, and Parkinson disease [185, 186, 190, 286-288]. In our hands, 
Cln3Δex7/8 mice display significant impairments in motor function, as evident by reduced 
latency to fall on the accelerating rotarod (Fig 2) [289], which has been attributed, in part, 
to excessive glutamatergic input [104, 263, 290, 291]. We utilized this rotarod deficit to 
determine whether three distinct PDE4 inhibitors, including an early generation 
(rolipram) [292], second generation (roflumilast) [221], and third generation (PF-
06266047) inhibitor could improve motor function in Cln3Δex7/8 mice over a 6 month 
treatment period. Administration of each PDE4 inhibitor was initiated in WT and 
Cln3Δex7/8 mice at 1 month of age and motor activity was assessed by repeat testing at 
monthly intervals throughout the study. 
We began our analysis with the first generation PDE4 inhibitor rolipram as proof-of-
principle, since the compound has demonstrated beneficial effects in a wide range of 
neurological disorders but was halted from further clinical development because of its 
adverse side effects [185, 186, 190, 286-288]. Rolipram exhibited a dose-dependent 
effect on motor behavior in Cln3Δex7/8 mice, where the highest concentration examined (5 
mg/kg/day) significantly improved motor function within the first month of treatment, 
which extended out to 4 months (Fig 2A). This benefit was negated with a lower drug 
concentration (0.5 mg/kg/day). Interestingly, WT mice receiving 5 mg/kg/day rolipram 
displayed increased rotarod performance as compared to vehicle treated WT animals at 
2-6 months (Fig 2A). A recent study demonstrated that long-term rolipram treatment in 
WT mice enhanced mGluR-mediated long-term depression (LTD) [293], which could 
account for our findings in WT animals although this remains speculative.  As mentioned 
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above, rolipram was not used for subsequent mechanistic studies in the Cln3Δex7/8 
model, since it is not a clinically viable agent because of its adverse side effects. 
 Roflumilast (DalirespTM) is an FDA approved PDE4 inhibitor used to reduce the risk 
of exacerbations in patients with chronic obstructive pulmonary disease (COPD) [222]. 
Since roflumilast is FDA approved, this offered the possibility of repurposing the 
compound for JNCL, should efficacy be demonstrated. Cln3Δex7/8 mice were treated with 
three different concentrations of roflumilast (2.5, 5, and 10 mg/kg) via daily oral gavage, 
with effects on motor function evaluated at monthly intervals. Only the highest doses of 
roflumilast tested (5 and 10 mg/kg/day) led to significant improvements in rotarod 
activity, whereas the lower concentration (2.5 mg/kg/day) was not effective (Fig 2B and 
data not shown). The group of WT and Cln3∆ex7/8 vehicle treated mice used to assess 5 
mg/kg/day roflumilast did not differ from each other dramatically in accelerating rotarod 
performance, which was unusual (Fig 2B). Nevertheless, treatment of Cln3∆ex7/8 animals 
with 5 mg/kg/day roflumilast did significantly improve motor performance compared to 
vehicle treated Cln3∆ex7/8 mice. Compared to rolipram, the beneficial effects of roflumilast 
on motor activity were not observed until 3 months of treatment, which may be explained 
by the lower blood-brain barrier permeability of roflumilast [221, 222]. 
 The final compound examined was a third generation PDE4 inhibitor PF-06266047 
(Patent Number, US 20140235612). A Phase 1 clinical trial has recently been completed 
to assess the safety and tolerability of PF-06266047 in healthy human subjects 
(ClinicalTrials.gov Identifier: NCT02539550). Unlike roflumilast, PF-06266047 has 
superior blood-brain barrier permeability and better rodent PK, which translated into 
lower dosages for our in vivo studies. Cln3Δex7/8 and WT mice received 0.5 or 1 mg/kg of 
PF-06266047 via daily oral gavage beginning at 1 month of age, with monthly rotarod 
assessments performed. Cln3Δex7/8 mice treated with the lowest dose of PF-06266047 
(0.5 mg/kg/day) displayed significant improvements in rotarod activity as early as one 
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month post-treatment, which was not observed with the higher dose (Fig 2C and data 
not shown). One possible explanation for this dosage-dependent effect is that the PK 
profile of PF-06266047 indicated that therapeutic levels would be maintained for ~24 h 
at the 1 mg/kg dose. Reducing the dose by a factor of 2 would inhibit enzyme activity for 
approximately 12 h, which was considered more desirable to allow for some PDE4 
activity that is likely needed to maintain homeostatic functions. Therefore, we interpreted 
the inability of the higher dose to provide benefit because it completely prevented PDE4 
action throughout a 24 h period. Based on this, PF-06266047 was examined at 0.5 
mg/kg/day for all subsequent studies. We also demonstrated that this dose of PF-
06266047 restored cAMP in the TH, VC, and HPC of Cln3Δex7/8 mice to levels seen in 
WT animals (Fig 3). 
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Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PDE4 inhibitors improve motor function in Cln3Δex7/8 mice. Cln3Δex7/8 and WT mice 
(n=8/group) received vehicle or (A and D) rolipram (RO; 0.5 or 5 mg/kg), (B and E) 
roflumilast (RF; 5 mg/kg), or (C and F) PF-06266047 (PF; 0.5 mg/kg) beginning at 1 
month of age, after which motor activity was assessed by accelerating rotarod testing at 
monthly intervals. Across all comparisons, significant differences between vehicle 
treated WT and Cln3Δex7/8 animals are denoted by asterisks (*). (A) Significant 
differences between Cln3Δex7/8 vehicle treated vs. Cln3Δex7/8 5 mg/kg/day rolipram are 
indicated by #, Cln3Δex7/8 vehicle treated vs. Cln3Δex7/8 0.5 mg/kg/day rolipram are 
denoted by †, and WT vehicle vs. WT 5 mg/kg/day rolipram are indicated by &. (B) 
Cln3Δex7/8 vehicle vs. Cln3Δex7/8 roflumilast treated mice are indicated by #, and WT 
vehicle vs. WT roflumilast are indicated by &. (C) Cln3Δex7/8 vehicle vs. Cln3Δex7/8 PF-
06266047 treated mice are indicated by #, and WT vehicle vs. WT PF-06266047 treated 
mice are indicated by &. (D-F) Weights of Cln3Δex7/8 and WT mice during PDE4 inhibitor 
treatment. (D) Significant differences between Cln3Δex7/8 vehicle treated vs. Cln3Δex7/8 5 
mg/kg/day rolipram are indicated by #, Cln3Δex7/8 vehicle treated vs. Cln3Δex7/8 0.5 
mg/kg/day rolipram are denoted by †, and WT vehicle vs. WT 5mg/kg/day rolipram are 
indicated by &. (E) Significant differences between WT vehicle and WT roflumilast are 
indicated by &. (F) Significant differences between Cln3Δex7/8 vehicle vs. Cln3Δex7/8 PF-
06266047 treated mice are indicated by #, and WT vehicle vs. WT PF-06266047 treated 
mice are indicated by &. For all comparisons, *, #, &, † reflect p < 0.05; **, ##, &&, †† 
denote p < 0.01; ***, ###, &&&, ††† reflect p < 0.001; and ****, ####, &&&& represent p 
< 0.0001. 
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Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PF-06266047 restores cAMP levels in Cln3Δex7/8 mice. Cln3Δex7/8 and WT mice received 
PF-06266047 (PF; 0.5 mg/kg) or vehicle via daily oral gavage beginning at 1 month of 
age, whereupon animals were sacrificed 6 months later for cAMP quantitation by 
immunofluorescence staining in the thalamus (TH), visual cortex (VC), and hippocampus 
(HPC) (n=5/group). Significant differences between groups are denoted by asterisks (***, 
p < 0.001; ****, p < 0.0001). 
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 To the best of our knowledge, chronic PDE4 inhibitor administration has not been 
examined in any juvenile species. When considering the possible utility of PDE4 
inhibitors in JNCL patients, safety/toxicity assessments are needed. To this end, weekly 
weight measurements and blood chemistry profiles (every 2-3 months) were conducted 
on WT and Cln3Δex7/8 mice receiving the various PDE4 inhibitors over the 6 month 
treatment period, with histopathology on multiple organs at the time of sacrifice. Both WT 
and Cln3Δex7/8 mice that received PDE4 inhibitors weighed less than their vehicle-treated 
counterparts; however, the rate of weight gain was similar between the groups (Fig 2D-
F). Blood chemistry analysis did not reveal any significant abnormalities in liver, kidney, 
or pancreatic function throughout the 6 month treatment period (data not shown), 
indicating that the compounds do not induce overt toxicity when chronically administered 
to juvenile animals. In addition, histopathological assessments of numerous organs did 
not reveal any evidence of toxicity as assessed by a board-certified pathologist (SMC; 
data not shown). 
 
PDE4 inhibitors attenuate disease-associated pathology in Cln3Δex7/8 mice.  
Prior work from our laboratory and others has identified early microglial and astrocyte 
activation in Cln3Δex7/8 mice that precedes and predicts regions of eventual neuronal loss 
[33, 227]. Additionally, Cln3Δex7/8 astrocytes show reduced expression of the glutamate 
transporter GLAST and glutamine synthetase, indicating altered glutamate recycling 
capacity, which supports the neurotransmitter imbalance associated with JNCL [104, 
227, 236, 281]. We have also reported that Cln3Δex7/8 microglia are primed towards a 
proinflammatory phenotype when exposed to danger signals present in the Cln3Δex7/8 
brain [123]. Given these findings and prior reports documenting the utility of PDE4 
inhibitors to dampen microglial proinflammatory activity and enhance glutamate 
transporter expression in astrocytes [283, 294], we examined whether PDE4 inhibitors 
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affected glial activation and glutamate transporter expression in Cln3Δex7/8 mice. We 
limited our analysis to roflumilast and PF-06266047 for these studies, since both agents 
demonstrated beneficial effects on motor function in Cln3Δex7/8 animals and are viable 
therapeutics to consider for use in JNCL patients (Fig 2B-C). 
Cln3Δex7/8 and WT mice were sacrificed after the 6 month PDE4 inhibitor treatment 
period, whereupon effects on microglial and astrocyte activation were examined by 
immunofluorescence staining for CD68 and GFAP, respectively. CD68 reactivity was 
significantly elevated in the S1BF and TH of Cln3Δex7/8 animals, which was attenuated 
following roflumilast treatment (Fig 4A and B). PF-06266047 also led to significant 
reductions in microglial activation (Fig 4C and D). GFAP immunoreactivity was 
significantly enhanced in the S1BF and TH of Cln3Δex7/8 mice as compared to WT 
controls (Fig 5), in agreement with previous observations from us and others [33, 227]. 
Roflumilast significantly reduced GFAP immunoreactivity in both brain regions of 
Cln3Δex7/8 mice (Fig 5A and B). Similar findings were obtained with PF-06266047, which 
significantly attenuated GFAP levels in the S1BF and TH of Cln3Δex7/8 animals (Fig 5C 
and D). Importantly, neither roflumilast nor PF-06266047 altered CD68 or GFAP 
expression in WT mice, supporting specific disease-modifying effects. 
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Figure 4.4 
 
 
 
PDE4 inhibitors attenuate microglial activation in Cln3Δex7/8 mice. Cln3Δex7/8 and WT 
mice (n=4-8/group) received vehicle, 5 mg/kg roflumilast (RF; A and B), or 0.5 mg/kg PF-
06266047 (PF; C and D) via daily oral gavage beginning at 1 month of age, whereupon 
animals were sacrificed 6 months later for quantitative assessments of microglial 
activation in the somatosensory barrel field cortex (S1BF) and thalamus by 
immunofluorescence staining for CD68. Significant differences between groups are 
denoted by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). 
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Figure 4.5 
 
 
 
PDE4 inhibitors reduce astrocyte activation in Cln3Δex7/8 mice. Cln3Δex7/8 and WT 
mice (n=4-8/group) received vehicle, 5 mg/kg roflumilast (RF; A and B), or 0.5 mg/kg PF-
06266047 (PF; C and D) via daily oral gavage beginning at 1 month of age, whereupon 
animals were sacrificed 6 months later for quantitative assessments of astrocyte 
activation in the somatosensory barrel field cortex (S1BF) and thalamus by 
immunofluorescence staining for GFAP. Significant differences between groups are 
denoted by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). 
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 JNCL is characterized by progressive lysosomal dysfunction, which is most 
pronounced in neurons [71, 72]. LAMP-1 is widely used as a readout of lysosomal 
pathology and is often considered a more sensitive indicator compared to inclusion 
burdens [295, 296]. Therefore, we evaluated the effects of PDE4 inhibitors on lysosomal 
pathology by LAMP-1 immunostaining. As has been shown for other LSDs [295, 297, 
298], LAMP-1 expression was increased in vehicle treated CLN3ex7/8 mice compared to 
WT animals in the S1BF and TH (Fig 6). Similar to what was observed for glial 
activation, both roflumilast and PF-06266047 significantly reduced LAMP-1 levels (Fig 
6A-B and C-D, respectively), reflecting reduced lysosomal pathology. Interestingly, 
neither roflumilast nor PF-06266047 had any effect on autofluorescent inclusions in 
either the brain or the retina (data not shown). This could be explained by the fact that 
drug treatment did not ensue until significant inclusion burdens had already developed at 
1 month of age and although the observed reductions in LAMP-1 suggest improvements 
in lysosomal biology, this was not sufficient to clear established inclusion material. 
However, the contribution of inclusions to neuronal death remains uncertain, since many 
inclusion-positive neurons are not lost in the disease [54, 60, 67]. 
 As previously mentioned, we recently reported significant reductions in the 
astrocytic glutamate transporter GLAST in 3 month-old Cln3Δex7/8 mice[227], which could 
represent one mechanism to account for excessive glutamate levels in JNCL that have 
been implicated in neuron excitotoxicity[104, 263, 290, 291]. This finding was extended 
in the current study, where significant reductions in GLAST expression were observed in 
the S1BF and TH of Cln3Δex7/8 mice at 7 months of age (Fig 7). Importantly, treatment of 
Cln3Δex7/8 animals with either roflumilast or PF-06266047 beginning at 1 month of age 
restored GLAST expression in both brain regions to similar levels seen in WT mice (Fig 
7A-B and C-D, respectively). Recent studies attributed elevated glutamate levels to 
rotarod deficits in Cln3Δex7/8 mice [236, 290] and our results support a potential link 
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between increasing the expression of molecules critical for glutamate homeostasis with 
improvements in motor activity in Cln3Δex7/8 animals. Importantly, neither roflumilast nor 
PF-06266047 altered LAMP-1 or GLAST expression in WT mice, supporting specific 
disease-modifying effects. Collectively, these results demonstrate the ability of two 
distinct PDE4 inhibitors to reverse some pathological features of Cln3Δex7/8 mice, which 
when coupled with improvements in motor behavior suggest that these compounds may 
offer therapeutic benefit in JNCL patients. 
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Figure 4.6 
 
 
 
PDE4 inhibitors attenuate lysosomal pathology in the Cln3Δex7/8 brain. Cln3Δex7/8 and 
WT mice (n=4-8/group) received vehicle, 5 mg/kg roflumilast (RF; A and B), or 0.5 mg/kg 
PF-06266047 (PF; C and D) via daily oral gavage beginning at 1 month of age, 
whereupon animals were sacrificed 6 months later for quantitative assessments of 
LAMP-1 expression in the somatosensory barrel field cortex (S1BF) and thalamus. 
Significant differences between groups are denoted by asterisks (**, p < 0.01; ****, p < 
0.0001). 
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Figure 4.7 
 
 
 
 
PDE4 inhibitors restore the loss of astrocytic GLAST expression in Cln3Δex7/8 mice. 
Cln3Δex7/8 and WT mice (n=4-8/group) received vehicle, 5 mg/kg roflumilast (RF; A and 
B), or 0.5 mg/kg PF-06266047 (PF; C and D) via daily oral gavage beginning at 1 month 
of age, whereupon animals were sacrificed 6 months later for quantitative assessments 
of GLAST expression in the somatosensory barrel field cortex (S1BF) and thalamus. 
Significant differences between groups are denoted by asterisks (*, p < 0.05; **, p < 
0.01; ****, p < 0.0001). 
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PDE4 inhibitors are capable of improving motor activity in Cln3Δex7/8 mice with 
advanced disease. Although roflumilast and PF-06266047 were capable of improving 
motor activity and disease-associated features in Cln3Δex7/8 mice when treatment was 
initiated at 1 month of age, we next examined whether delayed administration would be 
efficacious. This is an important issue in terms of translational potential, since a JNCL 
diagnosis can often be delayed and patients would have already experienced increasing 
disease burden. To this end, we began PDE4 inhibitor treatment in 3 month-old animals, 
which display more advanced disease in terms of increased lysosomal pathology and 
motor deficits. Delayed treatment with both roflumilast (5 mg/kg/day) and PF-06266047 
(0.5 mg/kg/day) significantly improved rotarod performance in Cln3Δex7/8 mice, with 
activity restored to near levels observed in WT animals (Fig 8A and B, respectively). 
Both WT and Cln3Δex7/8 mice receiving delayed PDE4 inhibitor treatment weighed less 
than their vehicle counterparts; however, weight gain occurred in all groups (Fig 8C and 
D). One interesting difference was observed with early vs. delayed roflumilast treatment 
of Cln3Δex7/8 mice, with 3 months treatment needed to demonstrate an effect when drug 
administration began at 1 month of age (Fig 3), whereas in animals with more advanced 
disease (i.e. 3 months) roflumilast improved motor function in Cln3Δex7/8 animals after 
only one month of treatment (Fig 8). The reason for this difference is not known; 
however, it could result from altered blood-brain barrier permeability with increasing 
disease burden at the time of treatment or PK differences in juvenile vs. adult animals. 
Collectively, these findings demonstrate the utility of PDE4 inhibitors to treat advanced 
disease, suggesting that they may offer therapeutic benefit to JNCL patients at later 
stages of the disease process. 
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Figure 4.8 
 
 
Delayed treatment with PDE4 inhibitors improves motor function in Cln3Δex7/8 mice. 
Cln3Δex7/8 and WT mice (n=8/group) received vehicle, 5 mg/kg roflumilast (RF; A and C) 
or 0.5 mg/kg PF-06266047 (PF; B and D) via daily oral gavage beginning at 3 months of 
age, after which motor activity was assessed by accelerating rotarod testing at monthly 
intervals. Across all comparisons, significant differences between vehicle treated WT 
and Cln3Δex7/8 animals are denoted by asterisks (*), Cln3Δex7/8 vehicle vs. Cln3Δex7/8 PDE4 
inhibitor treated mice are indicated by hash signs (#), and WT vehicle vs. WT PDE4 
inhibitor treated mice are indicated by ampersand signs (&). (C and D) Weights of 
Cln3Δex7/8 and WT mice receiving delayed PDE4 inhibitor treatment. Significant 
differences between Cln3Δex7/8 vehicle vs. Cln3Δex7/8 PDE4 inhibitor treated mice are 
indicated by #, and WT vehicle vs. WT PDE4 inhibitor treated mice are indicated by &. 
For all comparisons, *, #, & reflect p < 0.05; **, ##, && denote p < 0.01; ###, &&& reflect 
p < 0.001; and ****, ####, &&&& represent p < 0.0001. 
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DISCUSSION 
 Motor defects are a hallmark of JNCL [74], some of which are recapitulated in the 
Cln3Δex7/8 mouse model [289], as demonstrated by the rotarod deficits described in the 
current study. Prior reports using CLN3 knockout mice revealed heightened glutamate 
levels and reduced GABA in the cortex and cerebellum, and NMDA or AMPA receptor 
blockade could improve motor function in these animals, lending support to the 
excitotoxic theory of neuronal loss in JNCL [104, 236, 263]. Our recent work also 
supports this possibility, in that the expression of key molecules involved in glutamate 
clearance/detoxification from the synaptic cleft (GLAST and glutamine synthetase, 
respectively) were significantly reduced in the Cln3Δex7/8 brain [227]. In addition, we 
recently demonstrated transient hemichannel opening in Cln3Δex7/8 mice, which could 
exacerbate extracellular glutamate accumulation and promote excitotoxic neuronal death 
[227]. A second potential insult that may contribute to neuronal loss in JNCL is aberrant 
inflammatory activity that our laboratory has described in Cln3Δex7/8 microglia [123]. 
These potential non-cell autonomous effects of dysfunctional astrocytes and microglia in 
JNCL are expected to synergize with intrinsic neuronal defects to culminate in cell loss 
[299]. These changes led to our interest in investigating the utility of PDE4 inhibitors, 
since prior studies have shown their efficacy in attenuating microglial proinflammatory 
activity, augmenting astrocyte glutamate transporter expression, and delivering pro-
survival signals to neurons [283, 284, 294]. Our findings support a key role for cAMP in 
dictating motor dysfunction, glial activation, and lysosomal pathology in the Cln3Δex7/8 
brain, and support the feasibility of PDE4 inhibitors as potential therapeutics for the 
treatment of JNCL patients. 
 To our knowledge, this is the first report demonstrating significant cAMP reductions 
in the Cln3Δex7/8 brain in vivo. cAMP is a critical second messenger involved in regulating 
synaptic activity, glutamate homeostasis, and bioenergetic functions[183, 284]. cAMP 
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influences transcriptional events by binding to cAMP-responsive element binding protein 
(CREB), a ubiquitous transcription factor that controls the expression of a variety of 
genes, including synaptic proteins and glutamate receptors that are involved in 
glutamate release[284, 300]. Therefore, it is possible that generalized reductions in 
cAMP could affect downstream events responsible for optimal synaptic activity, 
behavior, and neuronal survival in JNCL. This was supported by our findings where 
three distinct PDE4 inhibitors (rolipram, roflumilast, and PF-06266047) were capable of 
restoring motor activity of Cln3Δex7/8 mice to performance levels near or equal to WT 
animals. Since prior work has implicated excessive glutamate stimulation as a major 
factor responsible for rotarod deficits in CLN3 knockout mice [236, 263] this suggests 
that PDE4 inhibitors may be modulating glutamatergic pathways. This was supported by 
our findings where chronic treatment of Cln3Δex7/8 animals with PDE4 inhibitors returned 
GLAST expression to levels observed in WT mice, which would be expected to help 
clear extracellular glutamate from the synapse and improve motor coordination. 
Importantly, both roflumilast and PF-06266047 were capable of improving motor activity 
in Cln3Δex7/8 mice when treatment was delayed until 3 months of age, revealing the ability 
of both compounds to benefit more advanced disease. With regard to roflumilast dosing, 
the group of WT and Cln3∆ex7/8 vehicle treated mice used to assess 5 mg/kg/day 
roflumilast (Fig 2B) did not differ from each other dramatically in accelerating rotarod 
performance, which was unusual. Nevertheless, treatment of Cln3∆ex7/8 animals with 5 
mg/kg/day roflumilast did significantly improve motor performance compared to vehicle 
treated Cln3∆ex7/8 mice and when considered in conjunction with its ability to attenuate 
microglial and astrocyte activation and lysosomal pathology, indicates that roflumilast 
exerts beneficial effects on CNS pathology at this dose. Increasing roflumilast to 10 
mg/kg/day improved accelerating rotarod performance even further in Cln3∆ex7/8 mice, 
which still reduced glial activation (data not shown); however, 10 mg/kg in mice is 
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nearing the maximal tolerated dose in humans of 500 µg/day [221, 222] and resulted in 
more weight loss in both WT and Cln3∆ex7/8 animals compared to 5 mg/kg/day (data not 
shown). This suggests that the dose required to improve motor activity may fall slightly 
above that needed to attenuate glial activation and lysosomal pathology and would 
require regular clinical assessments of JNCL patients to identify the optimal dose to 
improve motor coordination while minimizing known side effects of the compound (i.e. 
nausea and weight loss). To date, roflumilast is only FDA approved for adult use; 
however, one report examined the PK properties of a single roflumilast dose in children 
and adolescents with stable mild to moderate asthma and found that the drug was well-
tolerated with similar PK parameters to adults [301]. Chronic roflumilast dosing in 
children has not yet been performed but the authors speculated that this would be well-
tolerated, which is supported by our findings where chronic dosing of juvenile animals 
was not associated with severe adverse events. 
 One interesting observation was that both roflumilast and PF-06266047 also 
increased motor performance in WT animals. The reason for this is not clear, but may be 
explained by compensation in cAMP signaling. For example, the neuronal network 
maintains an optimal range for cAMP signaling in the brain [302]. Therefore, chronic 
cAMP elevations in WT mice, which would occur with continued PDE4 inhibitor 
treatment, likely increased cAMP-mediated signaling above the optimal range. This 
could result in an altered set point and manifest as improved motor performance, which 
was observed in the current study. Although WT mice demonstrated improved 
accelerating rotarod activity with chronic PDE4 inhibitor administration this did not 
translate to changes in glial activation, glutamate transporter expression, or lysosome 
biology, which were identical between WT animals treated with vehicle or PDE4 
inhibitors. In contrast, all three PDE4 inhibitors reduced disease-associated pathology in 
Cln3∆ex7/8 mice across all of the neurological readouts examined in this study, which 
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suggests that they are disease-modifying rather than symptomatic treatment. From a 
therapeutic perspective, PDE4 inhibitors would not be used in healthy individuals, but 
the inclusion of WT animals in the current study design was for completeness and to 
evaluate the potential toxicity of PDE4 inhibitors in juvenile animals, which has not yet 
been examined over a prolonged (6 month) interval. This was an important issue to 
address, since treatment of JNCL patients would require chronic dosing to impact 
disease progression. To this end, we did not observe any significant differences in blood 
chemistry values or tissue histopathology after a 6 month dosing period, although 
animals receiving PDE4 inhibitors weighed less than vehicle controls, but still showed 
weight gain throughout the study. 
 Another feature of JNCL is neuronal loss, which is more limited in Cln3 mouse 
models compared to human disease [32, 33]. A prior publication reported thalamic 
neuron loss in Cln3∆ex7/8 mice on a mixed 129Sv/Ev/CD1 background at 12 months [33]; 
however, this reduction was relatively modest and we have not observed any differences 
in neuron counts of Nissl stained sections in a 1 in 6 series using unbiased stereology 
between vehicle treated WT and Cln3∆ex7/8 animals on a C57BL/6 background, which is 
known to harbor milder disease phenotypes. The fact that we could not demonstrate 
evidence of neuronal loss in Cln3∆ex7/8 mice at this time point precluded our ability to 
assess the effects of PDE4 inhibitors on promoting neuronal survival. Therefore, our 
analysis has instead focused on other quantifiable pathological outcomes, including glial 
activation and lysosomal pathology. Nevertheless, at the conclusion of each dosing trial, 
brains were weighed and normalized to total body weight to account for weight loss 
resulting from chronic PDE4 inhibitor treatment. There were no significant changes in 
brain:body weight ratios between either vehicle treated WT and Cln3Δex7/8 mice or with 
any of the three PDE4 inhibitors tested, demonstrating that chronic PDE4 inhibitor 
dosing did not adversely affect neuron survival as measured by total brain weight. 
91 
 
 In addition to augmenting glutamate transporter expression, it is also possible that 
the beneficial effects of PDE4 inhibitors in Cln3Δex7/8 mice may be mediated, in part, by 
dampening neuroinflammatory responses that are suggested to occur in JNCL [33, 123, 
172, 227], since PDE4 inhibitors have been shown to reduce inflammation in other 
neurological conditions17-19, 24-26. The ability of PDE4 inhibitors to significantly reduce 
astrocyte and microglial activation in Cln3Δex7/8 mice supports this tenet. 
Neuroinflammation could be a risk factor in JNCL, since Cln3Δex7/8 microglia were shown 
to produce numerous proinflammatory cytokines (including TNF-α and IL-1β) when 
exposed to danger-associated molecular patterns (DAMPs) encountered during the 
disease process [123]. Another possibility is that Cln3Δex7/8 microglia could release 
DAMPs that induce reactive astrocytosis and impair glutamate homeostasis and other 
astrocyte functions[299]. Glial crosstalk could also occur via TNF-α and IL-1β production 
by Cln3Δex7/8 microglia that are known to induce astrocyte hemichannel opening[303], 
which we have also shown occurs in Cln3Δex7/8 mice and can lead to extracellular 
glutamate release [160, 227]. 
 Although lysosomal inclusions form throughout the body in JNCL due to the 
ubiquitous expression of CLN3, the primary site of disease manifestation is within the 
CNS. However, cardiac dysfunction is also observed in children as the disease 
progresses [304], and it remains unknown what systemic effects PDE4 inhibitors may 
exert in this context. Of note, besides the CNS, PDE4 isoforms are expressed in the 
cardiovascular system, the reproductive organs, the gastrointestinal tract, and the 
immune system where PDE4 inhibition has been associated with anti-inflammatory 
effects [305]. Since inflammation has been linked to pathology in JNCL, it is likely that 
PDE4 inhibitors may dampen inflammation, which would be desirable in the CNS to limit 
deleterious inflammation in response to dying neurons and autoantibody formation that 
is characteristic of the disease [166, 306]. We did not examine potential systemic effects 
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of PDE4 inhibitors in the current report, since there are no peripheral biomarkers that 
have been identified in JNCL and the few systemic changes reported to be altered in 
Cln3∆ex7/8 mice are modest in nature [102]. However, we did not observe any adverse 
effects on blood chemistry values throughout the 6 month duration of PDE4 inhibitor 
treatment in either Cln3∆ex7/8 or WT animals. Importantly, clinical studies have not 
revealed any severe adverse effects of roflumilast on the cardiac, reproductive, or 
gastrointestinal systems [221, 222]. 
 In summary, this study is the first to demonstrate the utility of PDE4 inhibitors to 
limit disease-associated attributes of JNCL. In particular, PDE4 inhibitors were found to 
improve motor function as well as mitigate astrocyte and microglial activation, reduce 
lysosomal pathology, and restore glutamate transporter expression in Cln3Δex7/8 mice. 
While the precise mechanisms whereby PDE4 inhibitors exert these beneficial effects 
are not known, targeting PDE4 represents a novel therapeutic strategy for JNCL 
patients. 
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Chapter 5: Self-complementary AAV9 gene delivery partially corrects pathology 
associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) 
Published Journal of Neuroscience 36(37):9669-82, 2016 
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ABSTRACT 
 Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) is a fatal lysosomal storage disease 
caused by autosomal recessive mutations in CLN3 for which no treatment exists. 
Symptoms appear between 5-10 years of age, beginning with blindness and seizures, 
followed by progressive cognitive and motor decline, and premature death (late teens-
20s). We explored a gene delivery approach for JNCL by generating two self-
complementary AAV9 (scAAV9) constructs to address CLN3 dosage effects using the 
methyl-CpG-binding protein 2 (MeCP2) and β-actin promoters to drive low vs. high 
transgene expression, respectively. This was based on the expectation that low CLN3 
levels are required for cellular homeostasis due to minimal CLN3 expression postnatally, 
although this had not yet been demonstrated in vivo. One month-old Cln3Δex7/8 mice 
received one systemic (i.v.) injection of scAAV9/MeCP2-hCLN3 or scAAV9/β-actin-
hCLN3, with GFP expressing viruses as controls. A promoter-dosage effect was 
observed in all brain regions examined, where hCLN3 levels were elevated 3- to 8-fold in 
Cln3Δex7/8 mice receiving scAAV9/β-actin-hCLN3 vs. scAAV9/MeCP2-hCLN3. However, 
a disconnect occurred between CLN3 levels and disease improvement, since only the 
scAAV9 construct driving low CLN3 expression (scAAV9/MeCP2-hCLN3) corrected 
motor deficits and attenuated microglial and astrocyte activation and lysosomal 
pathology. This may have resulted from preferential promoter usage, as transgene 
expression following i.v. scAAV9/MeCP2-GFP injection was primarily detected in NeuN+ 
neurons, whereas scAAV9/β-actin-GFP drove transgene expression in GFAP+ 
astrocytes. This is the first demonstration of a systemic delivery route to restore CLN3 in 
vivo using scAAV9 and highlights the importance of promoter selection for disease 
modification in juvenile animals. 
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INTRODUCTION  
 Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) is an autosomal recessive 
lysosomal storage disease (LSD) occurring in 1 per 100,000 live births [62]. JNCL is 
caused by mutations in CLN3 that result in loss of protein expression [60]. CLN3 
encodes a transmembrane protein primarily localized to the lysosome [234]; however, its 
function remains unknown [86]. JNCL is characterized by lysosomal inclusions 
composed of mitochondrial ATP synthase subunit C and lipids [307]. Despite the fact 
that disease symptoms are primarily neurological, there is no clear indication that 
lysosomal inclusions are directly responsible for neuron loss. This is because although 
most neurons exhibit evidence of lysosomal storage, only certain neuron populations die 
[8, 71, 72, 88]. 
 JNCL onset occurs between the ages of 5-10, presenting with rapid visual loss and 
seizures, progressive cognitive and motor decline [74], and premature death by the late 
teens-20s [232]. Neurodegeneration occurs in the cortex, cerebellum, and sub-regions of 
the hippocampus [77, 78]. Neuron loss has been reported in JNCL mouse models, but is 
relatively modest and not observed until late disease (i.e. 12-18 months), as opposed to 
early astrocyte and microglial activation (i.e. 1-3 months) [32, 159]. There is no cure for 
JNCL and current therapeutics only manage disease symptoms; therefore, we examined 
the feasibility of gene delivery to restore normal CLN3 function. Gene therapy has shown 
promise in other LSDs that involve mutations in soluble enzymes, in part, due to cross-
correction of non-transduced cells [213, 308]. The therapeutic bar is higher for JNCL 
because CLN3 encodes a transmembrane protein, presumably requiring more 
transduced cells to produce a phenotypic effect [87]. 
 Gene delivery via self-complementary adeno-associated virus 9 (scAAV9) has 
shown benefits in multiple neurodegenerative diseases including, spinal muscular 
atrophy and Rett syndrome [192-194]. AAV9 is an effective vector for CNS delivery 
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following systemic (i.v.) injection as it crosses the blood-brain barrier and transduces 
both neuronal and non-neuronal cells [204]. The scAAV9 genome is maintained as an 
episome in non-dividing cells, with studies reporting transgene expression for years 
[309, 310]. A prior study utilized a different AAV serotype (AAVrh.10/β-actin-hCLN3) in 
neonatal Cln3Δex7/8 mice, which required multiple intracranial injections and limited 
biodistribution [219]. In addition, Cln3Δex7/8 mice were treated at post-natal day 2, before 
disease-associated pathology manifested, and the identity of CNS transgene+ cells or 
behavioral assessments were not performed [219]. Our approach advances the field by 
employing a systemic delivery route to enhance virus biodistribution and a unique 
promoter (methyl-CpG-binding protein 2; MeCP2), which preferentially drives transgene 
expression in neurons when administered to juvenile (i.e. 1 month-old) Cln3Δex7/8 mice, at 
time at which disease burden has already manifested. 
 Two scAAV9 constructs were generated to address CLN3 dosage effects in vivo; 
one driving low CLN3 expression with the MeCP2 promoter that showed efficacy in Rett 
syndrome [193], and a second driving high CLN3 levels via the chicken β-actin promoter. 
This approach was based on the expectation that low CLN3 levels are required for 
cellular homeostasis due to minimal postnatal CLN3 expression [216], although this had 
not yet been demonstrated in vivo. One month-old Cln3Δex7/8 mice received a single i.v. 
injection of scAAV9/β-actin-hCLN3 or scAAV9/MeCP2-hCLN3, with GFP expressing 
viruses as controls. Only the scAAV9 construct driving low CLN3 expression 
(scAAV9/MeCP2-hCLN3) was capable of reducing motor deficits, glial activation, and 
lysosomal pathology in the Cln3Δex7/8 brain, whereas scAAV9/β-actin-hCLN3 and GFP 
viruses had no benefit. Collectively, this is the first demonstration of a systemic delivery 
route to restore CLN3 using scAAV9 and highlights the importance of promoter selection 
for modifying disease. 
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RESULTS 
Generation of scAAV9/CLN3 constructs to assess CLN3 gene dosage effects.  
 Unlike other NCL forms with deficiencies in soluble lysosomal enzymes, CLN3 
encodes a lysosomal transmembrane protein [60, 87, 234]. Therefore, although enzyme 
replacement therapy trials are currently underway to treat late-infantile neuronal ceroid 
lipofuscinosis (CLN2), where restoration of enzyme function in a larger number of cells is 
thought to occur by cross-correction, this is not feasible for JNCL. Another issue in the 
field was the expectation that low CLN3 expression is required for cellular homeostasis. 
This was based on earlier studies with CLN3-lacZ reporter mice, which revealed limited 
CLN3 expression postnatally, as well as btn1 mutant yeast (CLN3 ortholog) where 
overexpression was toxic [95, 99, 216]. However, a gene dosage effect for CLN3 has not 
yet been directly tested in vivo. To address this question, we generated two scAAV9 
constructs; one driving low CLN3 expression with the MeCP2 promoter and a second 
driving high CLN3 levels via the chicken β-actin promoter (Figure 1). 
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Figure 5.1 
 
 
 
 
 
 
Self-complimentary adeno-associated virus 9 constructs.  Each construct contains 
identical minimal SV40 intron (grey), human CLN3 cDNA (blue), bovine growth hormone 
polyadenylation signals (black) and viral inverted terminal repeats (red) to package self-
complementary virus. The first construct (top) contains the high expressing chicken β-
actin promoter (purple), while the second (bottom) contains the minimal essential 
promoter from the mouse MeCP2 gene (light blue). 
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Systemic administration of scAAV9 successfully crosses the blood-brain barrier 
to transduce neurons and astrocytes in juvenile CLN3ex7/8 mice.  
 In these studies, one month-old Cln3ex7/8 mice received a single i.v. injection of 
scAAV9/-actin-hCLN3, scAAV9/MeCP2-hCLN3, or GFP constructs, with vehicle treated 
WT and Cln3ex7/8 animals as controls. Virus administration was delayed to more 
accurately depict the age at which children are diagnosed with CLN3 disease (7-10 
years old) based on mouse-human age equivalent estimates [225] and when disease 
burden had already manifested. Throughout the 5 month study period, mice were 
weighed weekly and serum chemistry panels were performed every other month to 
assess potential toxicity. No significant changes in weight gain or serum chemistry 
profiles were observed throughout the study nor was there any evidence of systemic 
inflammation as measured by the presence of serum cytokines/chemokines (data not 
shown). These findings demonstrate that the scAAV9 constructs did not induce toxicity 
or systemic inflammation, which is in agreement with prior reports using scAAV9 in both 
mice and non-human primates [193, 194, 311]. 
  scAAV has a limited packaging capacity (i.e. 2.2 kb) [312], which required CLN3 
and GFP to be placed in separate viral constructs. In addition, this approach allowed 
virus biodistribution to be identified by GFP without interfering with CLN3 protein 
translation and function that could occur if a CLN3-GFP fusion construct was used. To 
assess scAAV9 biodistribution after a single i.v. injection of CLN3ex7/8 mice with 
scAAV9/-actin-GFP or scAAV9/MeCP2-GFP, the percentage of GFP+ cells and the 
specific cell types targeted was determined. Widespread GFP expression was observed 
with both the scAAV9/-actin-GFP and scAAV9/MeCP2-GFP constructs, with GFP 
detected throughout the brain, spinal cord, and eye (Figures 2 and 3). Interestingly, the 
percentage of GFP+ cells in several brain regions of Cln3ex7/8 mice receiving 
100 
 
scAAV9/MeCP2-GFP was higher at 5 months post-injection compared to scAAV9/-
actin-GFP (Figure 2A). The scAAV9/MeCP2-GFP construct primarily drove GFP 
expression in NeuN+ neurons (> 80% of GFP+ cells) in the somatosensory barrel field 
cortex (S1BF), thalamus (TH), and visual cortex (VC) with some GFAP+ astrocytes (< 
10% of GFP+ cells) also observed (Figure 2B-C). In contrast, scAAV9/-actin-GFP 
expression was more evident in astrocytes in the S1BF and VC (50-60% of GFP+ cells) 
compared to the scAAV9/MeCP2-GFP construct, although a few NeuN+ neurons (< 16% 
of GFP+ cells) were still detected with scAAV9/-actin-GFP (Figure 2B-C). These regions 
were selected since they have been reported to display significant increases in early glial 
activation as well as reduced neuron counts at advanced stages of disease (12-18 
months)[33, 159]. GFP expression was undetectable in microglia (data not shown), in 
agreement with previous reports showing that microglia are not permissive to AAV9-
mediated transduction [204, 313]. We also found that primary microglia were recalcitrant 
to scAAV9 transduction in vitro, whereas primary astrocytes were receptive (data not 
shown), confirming our in vivo findings. Along with widespread transduction in the brain, 
both scAAV9/-actin-GFP and scAAV9/MeCP2-GFP transduced the eye and spinal cord 
(Figure 3).  
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Figure 5.2 
 
 
 
 
 
Comparative biodistribution of scAAV9 constructs in the Cln3∆ex7/8 brain following 
systemic delivery. One month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. 
injection of 2x1012 vg of scAAV9/MeCP2-GFP or scAAV9/β-actin-GFP, whereupon 
animals were sacrificed at 5 months post-injection for analysis of virus biodistribution. A) 
Quantitation of total % GFP+ cells in the somatosensory barrel field cortex (S1BF), 
striatum (STR), suprachiasmatic nucleus (SCN), thalamus (VPM/VPL), hippocampus 
(CA1/CA3), and visual cortex (VC). B) Quantification of GFP+ neurons (NeuN+GFP+) and 
astrocytes (GFAP+GFP+) in the S1BF, thalamus (TH), and VC of scAAV9/β-actin-GFP 
vs. scAAV9/MeCP2-GFP treated mice. C) Tiled 40X confocal images depicting 
preferential GFP expression in NeuN+ neurons with scAAV9/MeCP2-GFP compared to 
scAAV9/β-actin-GFP, with both constructs targeting astrocytes. Significant differences 
are denoted by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001 as determined by paired 
t-test). 
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Figure 5.3 
 
 
 
Intravenous scAAV9 delivery successfully transduces the spinal cord and eye. 
One month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. injection of 2x1012 vg 
of scAAV9/MeCP2-GFP or scAAV9/β-actin-GFP, whereupon animals were sacrificed at 
13 months post-injection for analysis of virus biodistribution. Both scAAV9/β-actin-GFP 
and scAAV9/MeCP2-GFP transduced multiple cells with in the eye (A) and spinal cord 
(B). 
  
103 
 
 
Collectively, these results demonstrate that a single i.v. injection of scAA9 results in 
extensive CNS transduction and that the MeCP2 promoter preferentially drives 
transgene expression in neurons in one month-old mice, which does not occur with the 
-actin construct. Since we were unable to directly measure hCLN3 protein expression 
due to the lack of specific antibodies, combined with the limiting packaging size of 
scAAV9 vectors precluding the generation of a hCLN3/GFP bisictronic construct, it 
remains possible that hCLN3 biodistribution may differ slightly from GFP. However, 
since both the hCLN3 and GFP constructs utilized an identical capsid (AAV9) and 
promoters, monitoring GFP expression as a readout for cells that would also be 
expressing hCLN3 represented the best available approach and represents a strategy 
that has been widely used in other studies [314, 315]. 
 
The MeCP2 and -actin promoters exhibit a gene dosage effect in vivo. 
 A current viewpoint in the JNCL field is that postnatal CLN3 expression should be 
maintained at low levels to support homeostasis, whereas overexpression of CLN3 may 
be toxic [95, 99, 216]. This is suggested by CLN3 reporter mice and yeast studies with 
the CLN3 ortholog btn1; however, to date, there is limited in vivo evidence to support this 
tenant. To investigate whether a promoter dosage effect was evident between the β-
actin and MeCP2 constructs in vivo, Western blot analysis, immunofluorescence 
staining, and quantitative RT-PCR were conducted on multiple brain regions affected in 
JNCL. Western blot analysis confirmed that GFP expression driven by the β-actin 
promoter was up to 4-fold higher compared to the MeCP2 promoter (Figure 4A-B). This 
difference was also apparent in brain tissues by confocal microscopy, where images 
were collected using the same acquisition parameters (Figure 4C). Quantitative PCR 
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analysis revealed a 3- to 8-fold increase in hCLN3 expression driven by the scAAV9/-
actin vs. scAAV9/MeCP2 construct at 5 months post-injection in several brain regions 
(Figure 4D). hCLN3 protein expression could not be assessed, since currently available 
antibodies exhibit non-specific reactivity in both Western blots and immunostaining of 
brain tissues. hCLN3 mRNA expression was still detected at 13 months post-injection, 
the latest time point examined (data not shown). This finding reflects episome stability, 
which is in agreement with other reports where AAV9-driven transgene expression has 
been detected for years [193, 207, 310]. These data support widespread scAAV9-
mediated transgene expression throughout the CNS following a single i.v. injection and a 
promoter dosage effect in terms of transgene expression in vivo. 
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Figure 5.4 
 
 
Promoter dosage effect for transgene expression driven by the β-actin versus 
MeCP2 promoter.  One month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. 
injection of 2x1012 vg of scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, or GFP 
constructs, whereupon animals were sacrificed at 5 months post-injection for analysis of 
transgene expression in numerous brain regions. (A and B) Western blot of GFP 
expression in the striatum (STR), thalamus (TH), hippocampus (HP), visual cortex (VC), 
somatosensory barrel field cortex (S1BF), and cerebellum (CB) with raw (A) and 
quantitative (B) results expressed as fold-change. (C) Confocal images acquired with the 
same settings depict differences in GFP expression in the brain with animals injected 
with scAAV9/β-actin-GFP vs. scAAV9/MeCP2-GFP. (D) hCLN3 expression driven by the 
MeCP2 vs. β-actin promoters was determined by quantitative PCR following 
normalization to GAPDH and is presented as the fold-change in hCLN3 driven by 
scAAV9/β-actin relative to scAAV9/MeCP2. 
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Systemic delivery of scAAV9/MeCP2-hCLN3 reverses motor deficits in Cln3ex7/8 
mice, whereas scAAV9/-actin-hCLN3 is ineffective. 
 Unlike infantile and late-infantile NCL mouse models (CLN1 and CLN2, 
respectively), Cln3ex7/8 mice do not have a reduced lifespan [100]; however, animals 
develop robust and persistent motor deficits beginning at 2 months of age [67, 103]. To 
determine whether scAAV9/hCLN3 could reverse motor deficits in Cln3ex7/8 animals, 
Cln3ex7/8 mice receiving scAAV9/MeCP2-hCLN3, scAAV9/-actin-hCLN3, or GFP 
control constructs were subjected to monthly accelerating rotarod testing. As expected, 
the latency to fall was significantly lower in vehicle-treated Cln3ex7/8 mice compared to 
WT animals throughout the 5 month study period (Figure 5). Importantly, motor activity 
was restored to nearly WT levels only in Cln3ex7/8 mice receiving scAAV9/MeCP2-
hCLN3 as early as 1 month post-injection, whereas the scAAV9/-actin-hCLN3 and GFP 
constructs had no significant effect (Figure 5). Significant improvements in rotarod 
performance for Cln3ex7/8 mice receiving scAAV9/MeCP2-hCLN3 continued until 5 
months post-injection, the latest interval examined. We were not able to extend 
behavioral assessments beyond 5 months, since half of the animals in each group were 
sacrificed at this interval to assess virus biodistribution and transgene expression and 
the remaining group size was not sufficient to produce robust results. Collectively, these 
findings indicate that CLN3 delivery is able to improve motor performance in a JNCL 
mouse model. 
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Figure 5.5 
 
 
 
Peripheral delivery of scAAV9/MeCP2-hCLN3 corrects motor deficits in Cln3∆ex7/8  
mice. One month-old mice Cln3∆ex7/8 mice (n=5-8/group) received one i.v. injection of 
2x1012 vg of scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, or GFP constructs, with 
vehicle treated Cln3∆ex7/8 and WT animals as controls, whereupon motor coordination 
was assessed by monthly repeated accelerating rotarod assay, with results reported as 
latency to fall. Significant differences between WT vehicle and Cln3∆ex7/8 vehicle treated 
animals are denoted by asterisks, whereas significant changes between Cln3∆ex7/8 
vehicle and Cln3∆ex7/8 MeCP2-hCLN3 treated mice are denoted by hash signs (* or #, p < 
0.05; ** or ##, p < 0.01, using a repeated measures ANOVA with Tukey post-hoc 
analysis). 
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Systemic delivery of scAAV9/MeCP2-hCLN3 suppresses glial activation and 
reduces lysosomal pathology in the Cln3∆ex7/8 brain. 
 Reactive astrocytes and microglia are known to precede and predict regions of 
subsequent neuronal loss in JNCL mouse models [32, 33]. In addition, chronic microglial 
activation can create a toxic environment that induces and/or facilitates 
neurodegeneration [117]. A potential pathogenic role for microglia in JNCL is supported 
by our recent study demonstrating that Cln3ex7/8 microglia are primed to be 
proinflammatory [123]. To determine the effects of scAAV9/hCLN3 constructs on 
microglial activation, brain tissues were stained for CD68 at 5 months post-injection. 
Microglial activation was significantly increased in vehicle treated Cln3ex7/8 mice 
compared to WT animals in the TH and S1BF (Figure 6). In both brain regions, only the 
scAAV9/MeCP2-hCLN3 construct was able to significantly reduce microglial reactivity to 
near WT levels, whereas the scAAV9/-actin-hCLN3 and GFP constructs had no 
significant effect (Figure 6B). Similar findings were observed with regard to astrocyte 
activation. Reactive astrocytes were increased in Cln3ex7/8 mice compared to WT 
animals and only scAAV9/MeCP2-hCLN3 was able to reduce astrocyte activation, 
although this did not reach statistical significance (Figure 7). Neither the scAAV9/-actin-
hCLN3 nor GFP constructs influenced astrocyte reactivity in Cln3ex7/8 mice (Figure 7B). 
The selectivity of the scAAV9/MeCP2-hCLN3 construct to attenuate glial activation 
agrees with its ability to improve motor function, suggesting that either low levels of 
CLN3 expression or preferential transgene expression in neurons afforded by the 
MeCP2 promoter is critical. 
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Figure 5.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
scAAV9/MeCP2-hCLN3 reduces microglial activation in the Cln3∆ex7/8 brain. One 
month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. injection of 2x1012 vg of 
scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, or GFP constructs, with vehicle treated 
Cln3∆ex7/8 and WT animals as controls, whereupon microglial activation was evaluated by 
CD68 immunostaining in the thalamus and somatosensory barrel field cortex (S1BF) 
with representative images of the S1BF shown in (A) and quantitative analysis in (B). 
Significant differences are denoted by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001; 
****, p < 0.0001 using a mixed linear model).  
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Figure 5.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
scAAV9/MeCP2-hCLN3 reduces astrocyte activation in the Cln3∆ex7/8 brain. One 
month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. injection of 2x1012 vg of 
scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, or GFP constructs, with vehicle treated 
Cln3∆ex7/8 and WT animals as controls, whereupon astrocyte activation was evaluated by 
GFAP immunostaining in the thalamus and somatosensory barrel field cortex (S1BF) 
with representative images of the S1BF shown in (A) and quantitative analysis in (B). 
Significant differences are denoted by asterisks (*, p < 0.05 using a mixed linear model).  
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 JNCL is characterized by the progressive accumulation of autofluorescent storage 
material in lysosomes, which is most pronounced in neurons [71, 72]. Inclusions are 
composed of a heterogeneous mixture of mitochondrial ATP synthase subunit c 
(SCMAS), lipofuscin, and other protein aggregates [71, 72, 75, 307, 316]. While 
inclusions are not considered to be a direct cause of neuronal death, since many 
inclusion-positive neurons are not lost in the disease, inclusions are commonly used as 
a biomarker of disease progression [54, 60, 67]. The extent of LAMP-1 expression is 
also used as another readout of lysosomal dysfunction [295, 296]. Therefore, we 
evaluated the effects of scAAV9/hCLN3 constructs on lysosomal pathology by 
immunostaining for LAMP-1 and the major storage component SCMAS. As has been 
shown for other LSDs [295, 297, 298], LAMP-1 expression was increased in vehicle 
treated Cln3ex7/8 mice compared to WT animals in the TH and S1BF (Figure 8). Similar 
to what was observed for glial activation, only the scAAV9/MeCP2-hCLN3 construct was 
capable of reducing LAMP-1 levels in Cln3ex7/8 animals, whereas the scAAV9/-actin-
hCLN3 or GFP constructs had no effect (Fig 8B). As expected, SCMAS was significantly 
higher in vehicle treated Cln3ex7/8 mice compared to WT animals in the TH and S1BF 
(Figure 9). Cln3ex7/8 mice injected with scAAV9/MeCP2-hCLN3 displayed a trend 
towards lower levels of SCMAS in the S1BF, which was not evident with the scAAV9/-
actin-hCLN3 or GFP constructs (Figure 9B). It should be noted that virus injections 
occurred at 1 month of age, a time when significant lysosomal inclusions are already 
present [159], which may make it more difficult to observe dramatic reductions in storage 
material accumulation. 
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Figure 5.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of systemic scAAV9-hCLN3 delivery on lysosomal pathology in the 
Cln3∆ex7/8 brain. One month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. 
injection of 2x1012 vg of scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, or GFP 
constructs, with vehicle treated Cln3∆ex7/8 and WT animals as controls, whereupon 
immunofluorescence staining for LAMP-1 was performed in the thalamus and 
somatosensory barrel field cortex (S1BF) with representative images of the S1BF shown 
in (A) and quantitative analysis in (B). Significant differences are denoted by asterisks 
(***, p < 0.001; and ****, p < 0.0001, using a mixed linear model). 
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Figure 5.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of systemic scAAV9-hCLN3 delivery on lysosomal inclusions in the 
Cln3∆ex7/8 brain. One month-old mice Cln3∆ex7/8 mice (n=4-5/group) received one i.v. 
injection of 2x1012 vg of scAAV9/MeCP2-hCLN3, scAAV9/β-actin-hCLN3, or GFP 
constructs, with vehicle treated Cln3∆ex7/8 and WT animals as controls, whereupon 
immunofluorescence staining for SCMAS was performed in the thalamus and 
somatosensory barrel field cortex (S1BF) with representative images of the S1BF shown 
in (A) and quantitative analysis in (B). Significant differences are denoted by asterisks 
(****, p < 0.0001, using a mixed linear model). 
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DISCUSSION 
 Currently, no therapeutics exist for JNCL. Although lysosomal inclusions form 
throughout the body due to the ubiquitous expression of CLN3, the primary site of 
disease manifestation is the CNS [60]. Since neurons are the principle cell type lost 
during the disease, it was critical to devise a strategy to target this population at a 
relatively high frequency, since cross-correction is not possible based on the fact that 
CLN3 encodes for a transmembrane protein [87]. To this end, we utilized scAAV9 
harboring the human CLN3 cDNA under the control of either the high or low expressing 
β-actin and MeCP2 promoters, respectively, to assess potential gene dosage effects on 
disease outcome. β-actin is ubiquitously expressed and its promoter drives high 
transgene expression [317]. In contrast, the MeCP2 promoter is tightly regulated, since 
overexpression by ~2-fold produces neurological complications [318, 319]. MeCP2 
levels rise postnatally and continued expression is essential throughout adult life [320-
322], which would ensure that the exogenous MeCP2 promoter used here to drive 
hCLN3 is transcriptionally active in juvenile and adult animals. Since the MeCP2 
promoter is preferentially active in neurons [323], this also provides an attractive 
approach to correct intrinsic neuronal defects in JNCL. Indeed, a recent study utilizing 
the native MeCP2 promoter to drive wild type MeCP2 expression in a mouse model of 
Rett syndrome reported widespread neuronal transduction in the hippocampus, cortex, 
and cerebellum following systemic i.v. injection of adult animals, which rescued 
behavioral and cellular deficits [193]. In our study, we selected MeCP2 instead of the 
CLN3 promoter to drive low transgene expression, since the regulatory elements of 
CLN3 are not well-defined. 
 This study is the first to utilize systemic scAAV9 delivery to drive CLN3 expression 
in the CNS and importantly, only a single i.v. injection of scAAV9/MeCP2-hCLN3 was 
required to improve motor function, glial activation, and lysosomal pathology. In addition, 
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i.v. injection led to widespread transgene expression in the brain, spinal cord, and eye. 
scAAV9 did not negatively affect liver function as determined by blood chemistry 
analysis and all mice receiving scAAV9 constructs demonstrated equivalent weight gain. 
None of the scAAV9 constructs elicited signs of peripheral inflammation and there was 
no gross evidence of tumor formation in the liver at either 5 or 13 months post-injection 
(data not shown). Hepatocellular carcinoma has been reported in some mouse studies 
with specific AAV serotypes [324-326]; however, this is typically observed when virus is 
administered to neonatal mice [327, 328], which differs from our study where scAAV9 
was used in juvenile animals. Collectively, these findings demonstrate the safety and 
tolerability of scAAV9/hCLN3, which are important attributes when considering the 
potential translation of this gene delivery approach. 
 scAAV9 has been well characterized within the CNS following systemic i.v. injection 
[204, 311, 329-331]. Specifically, the AAV9 capsid allows the virus to cross the BBB, 
resulting in stable CNS transgene expression. Prior reports have demonstrated that the 
age at which animals are injected can influence virus biodistribution and cell type 
targeting. For example, i.v. injection of P1 mice with a scAAV9/β-actin-GFP construct led 
to a large population of transgene+ neurons and astrocytes [204]. In contrast, i.v. 
injections of mice that were P30 or older with scAAV9/β-actin-GFP primarily resulted in 
astrocyte targeting with few transgene+ neurons. Besides mouse age, the promoter used 
to drive transgene expression can also have a major impact. For example, i.v. injection 
of a scAAV9/MeCP2-MeCP2 construct in a mouse model of Rett syndrome led to robust 
transgene expression in neurons, despite the fact that animals did not receive the virus 
until adulthood (i.e. 2-3 months of age) [193]. Therefore, other mechanisms are at play 
besides age at injection, indicating that cell-type promoter preference may also influence 
transgene levels. In our studies, the scAA9/MeCP2-GFP construct led to significantly 
more transgene+ neurons than scAA9/β-actin-GFP, suggesting a promoter preference 
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for MeCP2 in neurons. This is also supported by studies showing that the MeCP2 
promoter is preferentially expressed in neurons as compared to glia [318, 319]. Since 
both the MeCP2 and β-actin constructs utilized the same viral capsid (AAV9), these 
differences likely result from promoter preferences in each cell population. 
 In terms of disease outcomes, only the scAAV9/MeCP2-hCLN3 construct was 
capable of improving motor function, attenuating glial activation, and reducing lysosomal 
pathology, all hallmarks of JNCL [32, 67]. However, it remains to be determined whether 
the beneficial effects of scAAV9/MeCP2-hCLN3 resulted from lower transgene levels or 
preferential expression in neurons. Because we did not observe any adverse effects with 
scAAV9/β-actin-hCLN3 that drives a 3- to 8-fold increase in hCLN3 depending on the 
brain region, this suggests that the beneficial effects of scAAV9/MeCP2-hCLN3 are likely 
due to preferential transgene expression in neurons. However, additional studies are 
needed to definitively address this possibility, including the generation of neuronal- and 
astrocyte-targeted hCLN3 constructs (i.e. synapsin-hCLN3 and GFAP-hCLN3, 
respectively). We are currently pursuing the longevity of scAAV9/MeCP2-hCLN3 gene 
transfer effects with larger cohorts of animals in conjunction with cell type selective 
targeting to neurons or astrocytes, such that coincident data can be collected with 
accelerating rotarod and histopathology (the former of which requires large group sizes 
of > 8). Preliminary analysis was performed with the limited numbers of Cln3Δex7/8 mice 
that were sacrificed at 13 months post-injection in the current study, including unbiased 
stereology to estimate neurons in the VPM/VPL thalamic nuclei. Although a prior study 
reported thalamic neuron loss in Cln3Δex7/8 mice on a mixed 129Sv/Ev/CD1 background 
at 12 months [33], this reduction was modest and we did not observe any differences in 
neuronal counts in the current study between vehicle treated WT and Cln3Δex7/8 animals 
on a C57BL/6 background, which is known to harbor milder disease phenotypes. The 
fact that we could not demonstrate evidence of neuronal loss in Cln3Δex7/8 mice 
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precluded our ability to assess the effects of CLN3 gene delivery on promoting neuronal 
survival. Nevertheless, we found that neuron counts in the thalamus were similar 
between WT animals and Cln3Δex7/8 mice receiving either the MeCP2 or β-actin hCLN3 
constructs at 13 months post-injection (data not shown). This indicates that CLN3 gene 
delivery did not exert any deleterious effects on neurons, which is an important indicator 
of safety. Likewise, although our results demonstrated that elevated hCLN3 expression 
driven by the β-actin promoter did not improve disease outcome, there was no evidence 
of toxicity, since scAAV9/β-actin-hCLN3 did not worsen motor performance, glial 
activation, lysosomal pathology, or blood chemistry values in Cln3ex7/8 mice. 
Collectively, these results indicate that unlike prior in vitro studies, elevated hCLN3 
expression in vivo is not deleterious, as determined by the readouts examined here. This 
is also supported by a study with rhAAV.10/β-actin-CLN3 where direct intracranial 
injection was not associated with adverse effects even though hCLN3 mRNA expression 
was elevated 12 to 100-fold [219]. 
 A major hallmark of JNCL is lysosomal storage material accumulation and although 
this heterogeneous material, primarily composed of SCMAS, has not been directly 
implicated in neuronal death [316], inclusion quantification is still widely used to assess 
lysosomal function and disease progression. Only scAAV9/MeCP2-hCLN3 led to 
reductions in SCMAS accumulation in Cln3ex7/8 mice, although this did not reach 
statistical significance. Another marker of lysosomal dysfunction is increased LAMP-1 
expression and similar to SCMAS, only scAAV9/MeCP2-hCLN3 was capable of 
significantly reducing LAMP-1 in the Cln3ex7/8 brain to WT levels. This finding was 
substantial given the fact that virus administration was delayed until 1 month of age, 
when significant lysosomal pathology had already manifested [159]. 
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 Like many other LSDs, JNCL mouse models are typified by early glial activation (i.e. 
1-3 months of age) that coincides with regions of modest neuronal loss that occurs much 
later in disease (i.e. 12-18 months; Pontikis et al., 2005; Burkovetskaya, 2014). While 
initial glial activation may represent a neuroprotective attempt, this clearly is not 
achieved and chronic inflammation can create a neurotoxic environment [34]. Indeed, 
our prior work revealed that Cln3ex7/8 microglia are primed to release exaggerated levels 
of numerous proinflammatory cytokines/chemokines [123]. Here we report that only the 
scAAV9/MeCP2-hCLN3 construct was able to reduce glial activation, which coincided 
with improvements in motor function. By extension, this suggests that either 1) reactive 
microglia and/or astrocytes contribute to CNS dysfunction in early disease; or 2) 
preferential transgene expression in neurons driven by the MeCP2 promoter improves 
neuronal homeostasis, such that surrounding glia do not sense neuronal danger signals 
and, as such, are less activated. These possibilities currently remain speculative and 
require additional studies using cell type-specific scAAV9 constructs. There is a long 
standing question of what occurs first, inflammation induced by reactive glia, or neurons 
releasing danger signals to induce glial activation and inflammation [172]. In other LSDs, 
such as Gaucher disease, inflammation is elicited by either neurons or astrocytes but not 
from microglia [332, 333]. In our studies, the scAAV9/-actin-hCLN3 construct 
predominantly drove transgene expression in astrocytes; however, it had no effect on 
glial activation. Furthermore, relatively fewer transgene+ astrocytes and no microglia 
were observed following scAAV9/MeCP2-hCLN3 injection. This implies that glia sense 
signals from diseased neurons, since most glia were still CLN3-deficient, yet their 
activation status was significantly reduced. This suggests that neurons are a primary 
driver of disease progression, although a confounding role from activated glia cannot be 
disregarded at this time. The importance of cell intrinsic CLN3 loss in neurons is also 
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supported by the finding that although the percentages of transgene+ cells were roughly 
similar with both viruses (Fig 2A), the MeCP2 construct resulted in significantly more 
transgene+ neurons compared to β-actin and was associated with therapeutic efficacy. 
This is likely attributed to preferential promoter activity in neurons, since both promoter 
constructs were delivered by the same viral capsid (AAV9). 
 In summary, a highly regulated, neuron-targeted promoter (MeCP2) restored motor 
function and decreased glial activation and lysosomal pathology in the Cln3ex7/8 brain. 
Our study is the first to show that systemic gene delivery with scAAV9 can be used to 
improve a lysosomal transmembrane mutation. This represents a critical first step 
towards a viable therapeutic for JNCL. 
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Chapter 6: General discussion and future directions. 
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JNCL is the most common pediatric neurodegenerative disease with an 
incidence of 2-4 in every 100,000 live births [60-62]. The disease is caused by mutations 
in CLN3, resulting in loss of a protein expression and impaired lysosomal function [60, 
233]. Children with CLN3 disease typically develop normally until symptoms present 
around 7-10 years of age, which are primarily neurological and include vision loss, 
seizures, and motor and cognitive decline [73-77]. While the CLN3 mutation is present in 
all cell types throughout the body, the CNS and neurons in particular are the most 
affected [71, 72, 158, 159, 334]. The exact function of CLN3 is currently unknown and 
there is no cure for JNCL, only palliative management. Therefore, is it imperative to 
investigate core pathways that are disrupted in JNCL to identify novel therapeutic targets 
to prolong patient survival. 
Previous studies have found that activated astrocytes and microglia precede and 
predict regions of future neurodegeneration in the thalamus, S1BF, and hippocampus 
[32, 33, 102]. Our laboratory found that Cln3Δex7/8 astrocytes have significantly reduced 
expression of the glutamate transporter GLAST and glutamine synthetase in multiple 
brains regions [159]. These astrocytic proteins are critical for regulating glutamate-
glutamine cycling and ensuring low extracellular glutamate concentrations are 
maintained [124-126]. Loss of these regulatory proteins supports the hypothesis that 
neuronal death is caused by excitotoxicity [104, 166, 167]. Recently, electrophysiology 
studies conducted in our laboratory found that neurons are hyperactive in 1-4-month-old 
Cln3Δex7/8 mice, which can lead to increases in glutamate release progressing to neuronal 
excitotoxicity [158]. Therefore, it was hypothesized that the CLN3 mutation causes 
abnormalities in astrocyte function to regulate the glutamate-glutamine cycle in JNCL.  
 Astrocytes influence neuronal activity and communicate with surrounding glia to 
interpret extracellular signals by Ca2+ fluctuations [246, 247].  When neurons release 
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glutamate, astrocyte transporters become active and increase intracellular Ca2+ levels to 
promote glutamate transporter expression at the plasma membrane, increase 
mitochondrial activity, and regulate neuronal firing. Astrocytes also send activity-
dependent Ca2+ signals to surrounding astrocytes via hemichannels and gap junctions 
effectively establishing a complex signaling syncytium [250-254]. To determine if 
astrocyte Ca2+ signaling networks were disrupted in the context of CLN3 disease, live 
cell imaging was used to record primary Cln3Δex7/8 astrocyte responses to glutamate. It 
was found that Cln3Δex7/8 astrocytes had significantly lower basal spontaneous Ca2+ 
oscillations as well as significantly lower Ca2+ responses when stimulated with high 
concentrations of extracellular glutamate. This phenotype was also found when 
astrocytes were pre-treated with pro-inflammatory cytokines to mimic an inflammatory 
milieu that cells might encounter in the JNCL brain. These results indicate that CLN3 
mutation causes a disruption in astrocyte Ca2+ signaling networks. Astrocytes interpret 
extracellular signals and relay information through Ca2+ to promote homeostasis; 
therefore, the fact that Cln3Δex7/8 astrocytes have significantly lower spontaneous Ca2+ 
oscillations under resting conditions suggests that they are incapable of monitoring the 
extracellular milieu. Low basal Ca2+ coupled with an inability to respond to glutamate 
stimulation implies that Cln3Δex7/8 astrocytes do not properly regulate synaptic activity 
allowing for continuous neuronal firing and increased glutamate release setting the stage 
for future neurodegeneration.  
 Glutamate regulation is an energy demanding process whereby astrocytes rely 
heavily on continuous metabolic support for energy [140, 141]. Previous studies have 
found that mitochondria in a Cln3Δex7/8 cerebellar neuron line have altered morphology, 
increased mitochondrial oxidative stress, and disrupted mitochondrial membrane 
depolarization, yet no studies have yet investigated astrocyte mitochondrial function in 
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real-time [89, 91, 256-258]. Utilizing a Seahorse mitochondrial bioassay, we found that 
Cln3Δex7/8 astrocytes displayed significant defects in mitochondrial respiration. In 
particular, Cln3Δex7/8 astrocytes had significantly lower basal respiration and ATP 
production under resting conditions. Mitochondrial disruption became even more 
apparent when Cln3Δex7/8 astrocytes were treated with either pro-inflammatory cytokines 
or C6 ceramide and neuronal lysate used to simulate DAMPs found in the JNCL brain. 
This phenotype was independent of mitochondrial number per cell, since Cln3Δex7/8 
astrocytes had significantly more mitochondria then WT cells, possibly due to disrupted 
mitophagy that has been reported in JNCL models. The loss of mitochondrial respiration 
in Cln3Δex7/8 astrocytes can be attributed, in part, to reduced Ca2+ signaling, as 
mitochondria rely heavily on intracellular Ca2+ concentrations. Mitochondrial respiration 
supplies large quantities of ATP for multiple cellular processes, including glutamate 
transport and metabolism. During times of heightened neuronal activity, astrocyte energy 
demands significantly increase. We have demonstrated that Cln3Δex7/8 astrocytes have 
significantly lower ATP production, suggesting that the cells do not have sufficient 
energy required for optimal glutamate transporter function. This would disrupt the 
glutamate concentration gradient, effectively increasing extracellular glutamate 
concentrations. During times of stress, astrocytes switch to a more glycolytic profile to 
compensate for increasing energy demands [136]. We found no significant differences in 
glycolytic rates between Cln3Δex7/8 and WT astrocytes, indicating that Cln3Δex7/8 cells were 
not able to compensate for reductions in mitochondrial respiration. Disrupted 
mitochondria not only effect the glutamate-glutamine regulation pathway but a multitude 
of other cellular processes, such as protein synthesis, Ca2+ regulation, and apoptotic 
processes, which may negatively impact the overall health of Cln3Δex7/8 astrocytes [335]. 
The mitochondrial defect in Cln3Δex7/8 cells could also be attributed to loss of lysosomal 
function. One of the main components of the lysosomal inclusions in JNCL is 
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mitochondrial ATP synthase subunit c, which implies a loss or disruption in mitochondrial 
turnover [336]. This would effectively propagate a negative feedback loop between 
lysosomal dysfunction and mitochondrial energy production.  
 While it is becoming increasingly apparent that Cln3Δex7/8 astrocytes contribute to 
glutamate dysregulation in JNCL, this is not an exclusively cell-autonomous process. It is 
hypothesized that neurodegeneration in JNCL is caused by excitotoxicity [104, 158]. 
This is based on studies reporting a loss of GABAergic inhibitory neurons and increased 
levels of glutamate in Cln3 -/- animals. However, no studies have directly examined the 
response of Cln3 neurons to glutamate. Our study found that primary Cln3Δex7/8 neurons 
were hyper-responsive to 25nM glutamate, which mimics levels normally released in the 
synaptic cleft after physiological neuronal firing. Cln3Δex7/8 neurons responded with 
significantly higher intracellular Ca2+ concentrations and while WT neurons also 
responded to glutamate stimulation, Ca2+ levels rapidly retuned to baseline, whereas 
intracellular Ca2+ remained elevated in Cln3Δex7/8 neurons for the duration of the 
experiment. This is an indication of excitotoxicity. Based on these results, we propose 
the following mechanism for neurodegeneration caused by excitotoxicity in JNCL. First 
the loss of CLN3 protein initiates lysosomal dysfunction in neurons, leading to the 
progressive accumulation of inclusions [159]. Unlike other NCL forms, the onset of 
disease symptoms in JNCL is protracted, suggesting compensatory mechanisms are in 
place until a certain pathological threshold is reached. At that time, neurons begin to 
become hyperreactive and overly sensitive to glutamate stimulation [159]. This leads to 
a continuous activation cycle that becomes unchecked due to the loss of GABAergic 
inhibitory neurons, which, in turn, causes a gradual rise in extracellular glutamate 
concentrations [33]. Astrocytes are the primary cell responsible for regulating glutamate 
release and clearance to prevent excitotoxicity. Astrocytes interpret the conditions in the 
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extracellular milieu and signal to surrounding cells through Ca2+ signaling. CLN3 
mutation disrupts astrocyte Ca2+ signaling under homeostatic conditions, indicating that 
the cells are refractory to communication or interpreting extracellular signals. When 
exposed to extracellular glutamate, the response of Cln3Δex7/8 astrocytes is significantly 
blunted, as revealed by low intracellular Ca2+ concentrations, suggesting that the cells 
are unable to properly respond to neuronal activity, which can cause a rise in 
extracellular glutamate. Increased extracellular glutamate disrupts concentration 
gradients and has been found to reduce astrocyte glutamate transporter expression 
[277]. Previous work from our laboratory has found that Cln3Δex7/8 mice have significantly 
lower expression of the glutamate transporter GLAST and glutamine synthetase [159]. 
The loss of these two key glutamate regulatory proteins suggests that Cln3Δex7/8 
astrocytes cannot compensate or clear elevations in extracellular glutamate, leading to 
glutamate accumulation in the tripartite synapse. Astrocytes require energy to maintain 
homeostatic processes and energy demands further increase during times of heightened 
neuronal activity [140, 141]. However, Cln3Δex7/8 astrocytes have significantly lower 
mitochondrial basal respiration and ATP production during both resting and disease-like 
conditions. This indicates that Cln3Δex7/8 astrocytes do not have the necessary energy-
generating pathways to properly regulate glutamate-glutamine cycling, neuronal activity, 
or other homeostatic processes, which, in turn, leads to a loss of glial support. At this 
point, both Cln3Δex7/8 neurons and astrocytes are likely undergoing stress that can trigger 
neuroinflammatory pathways to perpetuate disease progressing, leading to further glial 
activation and neurodegeneration. 
 As previously stated, there is currently no cure for JNCL. Since the exact function 
of the CLN3 protein is unknown, researchers must rely on targeting disrupted cellular 
pathways to develop new therapeutics. Developing a drug that is capable of affecting a 
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broad range of pathological mechanisms as well as cell types would be an ideal 
therapeutic for JNCL. PDE4 inhibitors have been found to be beneficial in multiple 
neurodegenerative diseases, such as AD, PD, and traumatic brain injury  [185, 186, 190, 
286]. These inhibitors have been found to reduce neuroinflammation, improve neuronal 
health and function, as well as augment glutamate transporter expression, all of which 
are pathways disrupted in JNCL [185, 186, 286].  PDE4 inhibitors function through 
regulating intracellular cAMP levels. Previous reports have ascertained that cAMP 
reductions impact neurobehavioral and cognitive functions during normal aging [182, 
183]. Low intracellular cAMP levels are known to be closely correlated with inflammatory 
activation and signaling pathways [282, 283]. Our study is the first to report that cAMP 
levels are significantly reduced in the thalamus and trending towards lower levels in the 
hippocampus and visual cortex of Cln3Δex7/8 mice at 7 months of age. This phenotype 
becomes progressively worse with time and by 12 months Cln3Δex7/8 mice have 
decreased cAMP concentrations in all 3 brain regions. This finding was confirmed by 
immunohistochemical staining. No significant differences in cAMP levels were identified 
in the somatosensory barrel field cortex (S1BF), indicating that cAMP disruption is 
region-dependent.  Based on these data we tested the efficacy of three distinct PDE4 
inhibitors, including rolipram (first generation), FDA-approved roflumilast (second 
generation) and PF-06266047 (PF, a third-generation drug obtained from Pfizer) in 
Cln3Δex7/8 mice. Animals were treated with each compound beginning at 1 month of age, 
which correlates with the onset of disease pathology. Multiple concentrations were 
utilized for each drug based on half-life and clearance to determine the optimal effective 
dose. To determine if PDE4 inhibitors had a positive effect on motor dysfunction in 
Cln3Δex7/8 mice, animals were tested on the accelerating rotarod to measure fine motor 
coordination. Each of the PDE4 inhibitors significantly improved motor coordination in 
Cln3Δex7/8 mice at different dosages. What was striking about this study was that rolipram 
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and PF improved motor activity as early as 1 month post-treatment, which was either 
maintained or progressively improved throughout the study. These findings suggest that 
PDE4 inhibitors act rapidly to improve neuronal function as well as slow disease 
progression. Roflumilast did not provide benefits until 3 months post-treatment, which is 
most likely due to its low BBB permeability [221]. Roflumilast is an FDA-approved 
pharmaceutical used to reduce the risk of inflammatory exacerbations in chronic 
obstructive pulmonary disease (COPD) and has been shown to be well-tolerated 
following a single dose in children with mild to moderate asthma [301]. Our studies found 
that all three PDE4 inhibitors did not cause any disruption to liver, kidney, or pancreatic 
function throughout the 6 month treatment course; however, weight loss was evident, 
which has been reported for this drug class. These findings offer the possibility that 
roflumilast can be repurposed for the treatment of JNCL patients, whereas PF has yet to 
undergo clinical trials for FDA-approval, which would take years.  
 One of the pathways modulated by PDE4 inhibitors is the glutamatergic pathway. 
As previously noted, glutamate transporter expression is reduced, which coincides with 
increased glutamate levels in the CNS of JNCL mouse models [104, 158, 159]. A 6 
month treatment period with roflumilast and PF significantly increased GLAST 
expression in the S1BF and thalamus of Cln3Δex7/8 mice. Concurrently, PF treatment 
significantly increased cAMP levels in the thalamus, visual cortex, and hippocampus. 
cAMP is known to promote neuronal homeostasis and regulate synaptic functions. It is 
that that raising cAMP levels has a synergistic effect on Cln3Δex7/8 neuron-astrocyte 
cross-talk by normalizing neuronal activity and increasing glutamate transporter 
expression to prevent excitotoxicity. This, in turn, would lead to improved neuronal 
health. Another indication that PDE4 inhibitors improved neuronal fitness was the finding 
that lysosomal pathology, which is primarily found in neurons, was significantly reduced 
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in Cln3Δex7/8 mice treated with PDE4 inhibitors. While the mechanism of action for this 
finding is unknown, improving overall neuronal health might reduce lysosomal stress and 
slow lysosomal dysfunction.  
By improving neuronal function, PDE4 inhibitors may establish a symbiotic 
environment with surrounding glial cells in Cln3Δex7/8 animals. Previously our laboratory 
has found activated astrocytes and microglia at later time points of disease and 
Cln3Δex7/8 microglia display a pro-inflammatory profile ex vivo. After roflumilast and PF 
treatment, microglial and astrocyte activation was significantly reduced in Cln3Δex7/8 mice 
as measured by CD68 and GFAP expression. These results indicate that increasing 
cAMP levels and improving neuronal health leads to reduced gliosis in the JNCL brain. 
By improving overall neuronal heath and limiting glial activation, PDE4 inhibitors have 
the ability to slow JNCL progression.    
Finally, it is important to note that PF and roflumilast significantly improved motor 
coordination in Cln3Δex7/8 mice even when treatment was delayed until 3 months of age. 
At this time point, Cln3Δex7/8 mice have more severe disease pathology, including 
significant motor deficits, increased lysosomal dysfunction, and glial activation. Both 
PDE4 inhibitors improved motor coordination after just a single month of treatment and 
Cln3Δex7/8 mice continued to improve out to 12 months of age. While we did not evaluate 
neuron survival at this interval, we speculate that PDE4 inhibitors prevented 
neurodegeneration due to the fact that rotarod performance was similar between 
Cln3Δex7/8 mice receiving PDE4 inhibitors and WT animals. These results suggest that 
PDE4 inhibitors can have a beneficial effect after disease pathology has developed. 
Many children with JNCL are often misdiagnosed in the beginning and by the time a 
proper diagnosis is made disease pathology has already begun to have detrimental 
effects on patients’ health. Therefore, PDE4 inhibitors appear to represent an excellent 
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potential therapeutic for JNCL because several are currently FDA-approved and 
commercially available, have shown efficacy in clinical trials of neurodegenerative 
diseases, and are able to significantly improve numerous pathological attributes in 
Cln3Δex7/8 mice, which closely recapitulate CLN3 disease in humans. 
While PDE4 inhibitors were successful in improving motor coordination and 
disease pathology, this is not a sustainable long-term approach, since they will not 
correct the underlying mutation. In this case the disease would continue to progress, 
albeit it at a slower rate. Therefore, we investigated the use of gene therapy as a more 
permanent therapeutic for JNCL. Because CLN3 is a transmembrane protein, cross 
correction is not possible, which requires a larger number of transduced cells for gene 
therapy to be beneficial. Therefore, we devised a strategy to utilize scAVV9 harboring 
hCLN3 driven by either the MeCP2 promoter (low expression level targeting neurons) or 
chicken β-actin promoter (high expression level targeting astrocytes) [193]. Separate 
scAAV9 constructs were generated with each promoter driving GFP to assess the 
identity of transfected cells. A dual hCLN3-GFP construct could not be generated, since 
the gene size exceeded the packaging capacity of scAAV9. This study was designed to 
test two hypotheses; first, to determine the efficacy of gene therapy to replace a 
transmembrane protein and second, to identify the appropriate CLN3 expression level 
required for cellular homeostasis. Previous gene therapy studies for NCLs have 
administered viruses via stereotaxic intracranial injections, which does not allow viral 
dissemination throughout the brain and provides obstacles for patient administration 
[219]. Therefore, we injected a single dose of scAAV9-hCLN3 or scAAV9-GFP 
systemically via retro-orbital injections into 1 month-old CLN3Δex7/8 mice to model the age 
of when children are diagnosed with JNCL. This approach is not only less invasive but 
also promotes transduction in the periphery, since cardiac defects manifest in CLN3 
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patients later in the disease process. Throughout the entirety of the study, mice exhibited 
no signs of toxicity, indicating that scAAV9 had no adverse side effects, which have 
been reported with retroviral therapies. Viral distribution was assessed at 5 months post-
injection, where transduction was widespread in several brain regions and also occurred 
in the spinal cord and eye, indicating that scAAV9 successfully crossed the BBB after 
intravenous injection. Viral-GFP expression was still found 1 year after injection in a 
small cohort of mice demonstrating scAAV9 stability in post-mitotic cells. This is 
important to highlight because it represents a more long-term clinical approach requiring 
a single non-invasive injection and a single treatment.           
 There is a long-standing hypothesis in the JNCL field that CLN3 protein 
expression must be maintained at low levels [95, 99, 216]. This theory is based on 
experiments demonstrating low levels of CLN3 mRNA expression throughout 
development and that CLN3 over expression is toxic to yeast. However, to date, no 
studies have been performed to directly investigate this question. To determine 
appropriate CLN3 expression levels, two different promoters were tested, namely, 
MeCP2 that is tightly regulated and maintained at low levels throughout life, and chicken 
β-active that is ubiquitously expressed and drives high transgene expression. Western 
blot analysis and RT-qPCR found that the β-actin promoter resulted in up to a 8-fold 
increase in hCLN3 mRNA expression compared to the MeCP2 promoter. Not only was 
there a difference in hCLN3 mRNA expression with the two promoters but also a cell-
type specific promoter preference. Specifically, scAAV9/MeCP2-GFP preferentially 
transduced neurons, whereas scAAV9/β-actin-GFP primarily targeted astrocytes. After 
12 months post-injection, unbiased stereology was performed to determine if hCLN3 
gene therapy was able to prevent neurodegeneration reported in other JNCL mouse 
models. However, there were no differences in neuronal counts between WT and 
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CLN3Δex7/8 vehicle treated mice, which made it impossible to discern any effects of 
scAAV9/MeCP-hCLN3 or scAAV9/β-actin-hCLN3 on CLN3Δex7/8 treated animals. This 
can possibly be attributed to the C57BL/6 genetic background of the CLN3Δex7/8 mice 
which have a milder disease phenotype compared to mice on the 129Sv/Ev/CD1 
background. However, these studies did establish that CLN3 overexpression from the 
chicken β-actin promoter did not cause any neurotoxicity. 
Once it was established that scAAV9 successfully transduced the CNS with high 
efficacy, effects on disease pathology were examined. Only CLN3Δex7/8 mice receiving 
scAAV9/MeCP-hCLN3 had improved motor function beginning at 1 month post-injection 
and continuing for up to 5 months (the latest time point examined), whereas scAAV9/β-
actin-hCLN3 had little to no effect. These results suggest that either low expression 
levels of CLN3 are required to maintain cellular homeostasis and/and restoring CLN3 
activity in neurons (with MeCP2) is more therapeutically beneficial than targeting 
astrocytes (with β-actin). Interestingly, only scAAV9/MeCP-hCLN3 reduced microglial 
activation in the thalamus and S1BF. While not direct evidence, this supports the theory 
that microglia activation is triggered by distressed signals from Cln3Δex7/8 neurons, since 
microglia were not transduced by scAAV9. Conversely, scAAV9/β-actin-hCLN3 had no 
effect on reducing microglial activation and in the case of the thalamus reactive microglia 
were more prominant than vehicle treated Cln3Δex7/8 mice. Coincident with microglia 
activation, only scAAV9/MeCP-hCLN3 reduced astrocyte activation in the thalamus and 
S1BF. One possible explanation for the, inability of scAAV9/β-actin-hCLN3, a primarily 
astrocyte targeted vector, to reduce astrocyte activation is that surrounding Cln3Δex7/8 
neurons were non-transduced and remained dysfunctional. Even though WT CLN3 was 
restored in many Cln3Δex7/8 astrocytes with scAAV9/β-actin-hCLN3, the cells are still 
unable to cope with neuronal defects, further supporting the idea that neurons and not 
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inflammation or glial reactivity plays a larger role in disease pathology. Finally, lysosomal 
pathology was assessed by monitoring two commonly used makers, namely LAMP-1 
and mitochondrial ATP synthase subunit C (SCMAS), a primary component of lysosomal 
aggregates in JNCL. Similar to previous results, only scAAV9/MeCP-hCLN3 reduced 
LAMP-1 expression and SCMAS inclusions. This finding was significant, since virus was 
administered at a time point when significant lysosomal dysfunction and inclusion 
burdens have already manifested in Cln3Δex7/8 mice (i.e. 1 month of age). These results 
suggest that scAAV9/MeCP-hCLN3 is capable of improving lysosomal function and 
preventing further inclusion development. Collectively, this data indicate that gene 
therapy may be a viable long-term therapeutic option for JNCL.    
Future directions and outstanding questions 
 The work presented in this dissertation has provided new insights into the role of 
astrocyte and neuron dysfunction in JNCL as well as identified novel therapeutic 
strategies that have the potential to slow disease progression and prolong survival for 
JNCL patients. However, there are still many unanswered questions. The first of which is 
centered on early neuronal dysfunction that potentially creates a toxic extracellular milieu 
and induction of neuroinflammatory pathways. The CLN3 mutation is present in all cell 
types throughout the body, yet neurons are the most dramatically affected [71, 72, 158, 
159, 334]. As previously discussed, we found that Cln3Δex7/8 neurons are hypersensitive 
to glutamate stimulation in vitro and are hyperactive in the visual cortex and 
hippocampus of Cln3Δex7/8 mice between 1-4 months of age in vivo. To date, there have 
been no studies that have directly shown how the loss of lysosomal function leads to 
hyperactive neurons. Therefore, it is vital to elucidate these pathways to gain a better 
understanding of events that trigger neurodegeneration in JNCL. Another interesting 
question is why JNCL disease progression is more protracted compared to INCL and 
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LNCL [79]. The delay in JNCL symptom manifestation suggests the existence of 
compensatory mechanisms that prevent cellular demise until a threshold of pathology is 
achieved. It is unknown what this mechanism(s) might be but if determined this could be 
a therapeutic target to promote compensatory mechanisms and slow disease 
progression. With regard to new therapeutic development, it would be informative to 
determine which cell type plays a dominant role in disease progression. This can be 
achieved with scAAV9 engineered with cell type-specific promoters, such as 
synaptophysin for neurons and GFAP for astrocytes. It would also be interesting to delve 
deeper into Cln3Δex7/8 neuron pathology by placing hCLN3 expression under the control 
of GABAergic or glutamatergic promoters to examine the role excitatory versus inhibitory 
neurons play in disease progression. Since the identification of CLN3 as the causative 
mutation for JNCL in 1995, many important discoveries have been made in this field in 
an effort to improve the quality of life and survival of children afflicted with JNCL, with the 
hope of one day finding a cure for this fatal LSD. 
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